Hcmv entry inhibitors

ABSTRACT

Subject matter of the present invention is a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold for inhibiting HCMV entry for use in a method of treatment in a subject that has been infected by HCMV or for use in a method of prophylaxis of HCMV infection in a subject that has not yet been infected by HCMV.

Subject matter of the present invention is a soluble PDGFR-alpha-Fcchimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibodyor a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffoldfor inhibiting HCMV entry for use in a method of treatment in a subjectthat has been infected by HCMV or for prophylaxis of HCMV infection in asubject that has not yet been infected by HCMV.

Human cytomegalovirus (HCMV) is a pathogenic human beta-herpesvirus,which like other beta-herpesviruses can only replicate in its specifichost. Primary infection is followed by lifelong latent persistence andoccasional reactivation of the virus, which usually goes unnoticed bythe infected individual. However, under conditions of insufficientimmune responses, HCMV can cause severe or even life threateningdisease, e.g. in AIDS patients, transplant recipients, and infectedfetuses after intrauterine infection. Antiviral drugs are available butassociated with significant adverse effects and the development ofresistance (3, 15). Therefore, alternative treatment options aredesired.

One powerful antiviral strategy is the inhibition of entry into thecell, and its effectiveness against HCMV is exemplified by theneutralizing activity of anti-HCMV antibodies (5, 12, 13, 23, 26, 30,31, 36). While the therapeutic use of antibodies may be limited as theyare difficult to engineer, other entry inhibitors are also conceivablefor HCMV. In case of HIV, small molecules and peptides have already beenapproved for antiviral therapy (17); a peptide-based entry inhibitoragainst Hepatitis B virus is in clinical trial (34); and with picornaviruses, an Fc-CAR fusion protein inhibits viral entry and is effectivein animal models, but has not yet been developed for clinical use (14,29, 41).

HCMV is an enveloped virus and has to fuse its membrane with the hostmembrane for penetration of the nucleocapsid into the cytoplasm, fromwhere it is then transported to the nucleus and releases the viralgenome into the nucleoplasm. Several glycoprotein complexes in theenvelope of HCMV particles have been described that contribute to entryof HCMV into its target cells and are therefore potential targets ofentry inhibitors (7, 8, 20, 22, 24, 27). In analogy to otherherpesviruses, homotrimers of glycoprotein B (gB) are assumed to exertthe fusion between viral envelope and cellular membrane, whileheterotrimers of gH, gL and gO are necessary to promote this fusionprocess (4, 6, 9, 18, 42). On certain cell types including endothelialand epithelial cells, a pentameric complex is required in addition foreffective entry, which consists of gH, gL, and three accessory proteinsfrom the viral UL128 gene (1, 2, 16, 37, 42).

On the cellular side, numerous proteins have been proposed as entryreceptors of HCMV, including various integrins, the epithelial growthfactor receptor (EGFR) and the platelet-derived growth factor receptoralpha (PDGFR-alpha), but have been controversially discussed (11, 21,33, 35, 38, 39) (reviewed in (2)).

The inventors surprisingly and unexpectedly found that the extracellularpart of PDGFR-alpha is a highly potent entry inhibitor of HCMV in eithercell type, and peptides derived from this molecule are also effective,thus providing a rationale for the development of PDGFR-alpha basedanti-HCMV therapeutics.

Thus, subject matter of the present invention is a solublePDGFR-alpha-Fc chimera for inhibiting HCMV entry for use in a method oftreatment in a subject that has been infected by HCMV or for prophylaxisof HCMV infection in a subject that has not yet been infected by HCMV,wherein said soluble PDGFR-alpha-Fc chimera comprises a PDGFR-alphasequence selected from the group comprising:

I. SEQ ID No. 2 (aa 24 to aa 524 of SEQ ID No. 1):QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHLYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEESKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE,

-   -   II. a sequence having 90% or more identity to SEQ ID No. 2    -   III. a sequence that is a truncated sequence of SEQ ID No. 2 or        a sequence having 90% or more identity to said truncated SEQ ID        No. 2, said sequence having at least 45 amino acids, and    -   IV. variants of sequences according to the aforementioned items        I., II., III., with substitutions at one or more of the        following positions (numbering is adhered to SEQ ID. No. 1):        -   Ile-30, Glu-52, Ser-66, Ser-67, Asp-68, Leu-80, Ser-89,            His-162, Pro-169, Asp-173, Ile-188, Val-193, Lys-194,            Glu-213, Lys-304, Thr-320, His-334, Arg-340, Ile-373,            Lys-378, Ala-396, Ala-401, Thr-436, Thr-440, Ile-453,            Val-469, Ile-476, Ser-478, Asp-480, Ser-482, Arg-487.

Percentage of sequence identity is calculated for the shortened peptidein case of truncated peptide (i.e. variants). Introduction of additionalamino acids are handled as gap in the original sequence, deletions arehandled as gap in the modified peptide for calculation of sequenceidentity. A truncated sequence of a Sequence is a fragment of saidSequence.

Truncated sequence of SEQ ID No. 2 means the sequence of SEQ ID No. 2,wherein certain amino acid (stretches) within said sequence are deleted.SEQ ID No. 3 is e.g. a truncated sequence of SEQ ID No. 2. A truncatedsequence of SEQ ID No. 2 is a fragment of said sequence.

A sequence that is a truncated sequence of SEQ ID No. 2 or a sequencehaving 90% or more identity to said truncated SEQ ID No. 2 has at least45 amino acids, preferably at least 80 amino acids, more preferably atleast 100 amino acids, even more preferred at least 150 amino acids.

“Soluble PDGFR-alpha-Fc chimera” means that the respective PDGFR-alphaderivate can be dissolved in biocompatible solutions, preferably saline,at a concentration of at least 100 N g/ml.

“HCMV” means Human cytomegalovirus.

Also, subject matter of the present invention is a solublePDGFR-alpha-Fc chimera for inhibiting HCMV entry for use in a method oftreatment in a subject that has been infected by HCMV or for prophylaxisof HCMV infection in a subject that has not yet been infected by HCMVaccording to the invention, wherein said soluble PDGFR-alpha-Fc chimerainhibits HCMV entry.

Inhibition of HCMV entry is determined by measuring the reduction ofinfectivity of HCMV in cell culture assays, as follows:

Infectious cell free HCMV preparations (corresponding to a multiplicityof infection of 1) are pre-incubated with the substance (at variableconcentrations) for 2 h at 37° C. The pre-incubated mixture of HCMV andsubstance is added to cell cultures of choice, including at least aculture of human primary fibroblasts and a culture of human endothelialcells. Cells are incubated with the mixture for 2 h at 37° C. Themixture of HCMV and substance is then replaced with the appropriate cellculture medium and cells are further incubated for at least 16 h at 37°C. HCMV infection of the cells is detected by immunostaining of HCMVimmediate early antigens (pUL122/123) with indirect immunofluorescence.The ratio of HCMV-IE antigen-positive cells per total cells iscalculated as a readout for the efficiency of viral entry. The EC₅₀ isdetermined as the concentration of the substance (given in ng/ml) thatreduces the fraction of infected cells in any of the tested cell typesby 50% as compared to controls in with HCMV has been pre-incubated withmedium (minimal essential medium with 5% fetal calf serum) instead ofthe substance.

If the substance is a PDGFR-alpha-Fc chimera, it is regarded effectiveif the EC₅₀ in the assay described above is lower than 1000 ng/ml,preferably lower than 100 ng/ml.

If the substance is a peptide, it is regarded effective if the EC₅₀ inthe assay described above is lower than 10 nmol/ml, preferably lowerthan 0.5 nmol/ml.

If the substance is an antibody, it is regarded effective if the EC₅₀ inthe assay described above is lower than 5 μg/ml, preferably lower than0.5 μg/ml.

In one embodiment of the invention a soluble PDGFR-alpha-Fc chimera isused for inhibiting HCMV entry in a method of treatment in a subjectthat has been infected by HCMV or used for prophylaxis of HCMV infectionin a method of treatment of a subject that has not yet been infected byHCMV according the invention wherein said soluble PDGFR-alpha-Fc chimerahas at least one of the following mutations or deletions within SEQ IDNo. 2 (numbering is adhered to SEQ ID No. 1):

-   -   i. Deletion of aa 150-189,    -   ii. Deletion of aa 150-234,    -   iii. Deletion of aa 150-290,    -   iv. Deletion of aa 150-524,    -   v. Deletion of aa 24-100 and deletion of aa 150-234,    -   vi. SEQ ID No. 2 having at least one point mutation in at least        one of the protein regions as specified above under items i.,        ii., iii., iv., v . . . .

In another embodiment of the invention a soluble PDGFR-alpha-Fc chimerais used that is suitable for inhibiting HCMV entry in a method oftreatment in a subject that has been infected by HCMV or used forprophylaxis of HCMV infection in a method of treatment of a subject thathas not yet been infected by HCMV according the invention wherein saidsoluble PDGFR-alpha-Fc chimera has at least one of the followingmutations or deletions within SEQ ID No. 2 (numbering is adhered to SEQID No. 1):

-   -   i. Deletion of amino acids M133-I139 (optionally having        additional deletions at the N- and/or C-termini of at least one        or at least two or at least three N-terminal amino acids and/or        at least one or at least two or at least three or at least four        or at least five C-terminal amino acids, wherein each of the        respective combinations of additional deletions, e.g., one        N-terminal plus one C-terminal deletions; two N-terminal plus        three C-terminal deletions, three N-terminal and five C-terminal        deletions shall are given here as examples for all possible        combinations of additional deletions at the respective ends of        amino acids M133-I139; further it is possible also to delete one        or two or three or four or five amino acids less than amino        acids M133-I139 at the N-terminus and/or the C-terminus, wherein        all possible combinations of fewer deleted amino acids are        possible, provided that at least one amino acid remains deleted        in the stretch of amino acids M133-I139),    -   ii. Deletion of amino acids V184-G185 (optionally having        additional deletions at the N- and/or C-termini of at least one        or at least two or at least three N-terminal amino acids and/or        at least one or at least two or at least three or at least four        or at least five C-terminal amino acids, wherein each of the        respective combinations of additional deletions, e.g., one        N-terminal plus one C-terminal deletions; two N-terminal plus        three C-terminal deletions, three N-terminal and five C-terminal        deletions shall be given here as examples for all possible        combinations of additional deletions at the respective ends of        amino acids V184-G185; Furthermore, it is possible also to        delete one amino acid less than amino acids V184-G185 at the        N-terminus and/or the C-terminus, wherein all possible        combinations of fewer deleted amino acids are possible, provided        that at least one amino acid remains deleted in the stretch of        amino acids V184-G185),    -   iii. Deletion of amino acids N204-Y206 (optionally having        additional deletions at the N- and/or C-termini of at least one        or at least two or at least three N-terminal amino acids and/or        at least one or at least two or at least three or at least four        or at least five C-terminal amino acids, wherein each of the        respective combinations of additional deletions, e.g., one        N-terminal plus one C-terminal deletions; two N-terminal plus        three C-terminal deletions, three N-terminal and five C-terminal        deletions shall are given here as examples for all possible        combinations of additional deletions at the respective ends of        amino acids N204-Y206; furthermore, it is possible also to        delete one or two amino acid less than amino acids N204-Y206 at        the N-terminus and/or the C-terminus, wherein all possible        combinations of fewer deleted amino acids are possible, provided        that at least one amino acid remains deleted in the stretch of        amino acids N204-Y206);    -   iv. Deletion of amino acids N240-L245 (optionally having        additional deletions at the N- and/or C-termini of at least one        or at least two or at least three N-terminal amino acids and/or        at least one or at least two or at least three or at least four        or at least five C-terminal amino acids, wherein each of the        respective combinations of additional deletions, e.g., one        N-terminal plus one C-terminal deletions; two N-terminal plus        three C-terminal deletions, three N-terminal and five C-terminal        deletions shall are given here as examples for all possible        combinations of additional deletions at the respective ends of        amino acids N240-L245; further it is possible also to delete one        or two or three or four or five amino acids less than amino        acids N240-L245 at the N-terminus and/or the C-terminus, wherein        all possible combinations of fewer deleted amino acids are        possible, provided that at least one amino acid remains deleted        in the stretch of amino acids N240-L245),    -   v. Deletion of amino acids T259-E262 (optionally having        additional deletions at the N- and/or C-termini of at least one        or at least two or at least three N-terminal amino acids and/or        at least one or at least two or at least three or at least four        or at least five C-terminal amino acids, wherein each of the        respective combinations of additional deletions, e.g., one        N-terminal plus one C-terminal deletions; two N-terminal plus        three C-terminal deletions, three N-terminal and five C-terminal        deletions shall are given here as examples for all possible        combinations of additional deletions at the respective ends of        amino acids T259-E262; further it is possible also to delete one        or two or three or four amino acids less than amino acids        T259-E262 at the N-terminus and/or the C-terminus, wherein all        possible combinations of fewer deleted amino acids are possible,        provided that at least one amino acid remains deleted in the        stretch of amino acids T259-E262);    -   vi. Deletion of amino acids K270-T273 (optionally having        additional deletions at the N- and/or C-termini of at least one        or at least two or at least three N-terminal amino acids and/or        at least one or at least two or at least three or at least four        or at least five C-terminal amino acids, wherein each of the        respective combinations of additional deletions, e.g., one        N-terminal plus one C-terminal deletions; two N-terminal plus        three C-terminal deletions, three N-terminal and five C-terminal        deletions shall are given here as examples for all possible        combinations of additional deletions at the respective ends of        amino acids K270-T273; further it is possible also to delete one        or two or three amino acids less than amino acids K270-T273 at        the N-terminus and/or the C-terminus, wherein all possible        combinations of fewer deleted amino acids are possible, provided        that at least one amino acid remains deleted in the stretch of        amino acids K270-T273);    -   vii. Deletion of amino acids Q294-E298 (optionally having        additional deletions at the N- and/or C-termini of at least one        or at least two or at least three N-terminal amino acids and/or        at least one or at least two or at least three or at least four        or at least five C-terminal amino acids, wherein each of the        respective combinations of additional deletions, e.g., one        N-terminal plus one C-terminal deletions; two N-terminal plus        three C-terminal deletions, three N-terminal and five C-terminal        deletions shall are given here as examples for all possible        combinations of additional deletions at the respective ends of        amino acids Q294-E298; further it is possible also to delete one        or two or three or four amino acids less than amino acids        Q294-E298 at the N-terminus and/or the C-terminus, wherein all        possible combinations of fewer deleted amino acids are possible,        provided that at least one amino acid remains deleted in the        stretch of amino acids Q294-E298);    -   viii. SEQ ID No. 2 having at least one point mutation in at        least one of the protein regions as specified above under items        i., ii., iii., iv., v., vi, or vii.

One embodiment is a soluble truncated or mutated version ofPDGFR-alpha-Fc chimera that is used for inhibiting HCMV entry in amethod of treatment in a subject that has been infected by HCMV or foruse in prophylaxis of HCMV infection in a subject that has not yet beeninfected by HCMV according to the invention, wherein said solubletruncated or mutated version of PDGFR-alpha-Fc chimera inhibits HCMVentry and shows reduced ability to inhibit the biological activity ofPDGF-type growth factors as compared to the inhibitory effect of wildtype chimeras.

A soluble truncated or mutated version of PDGFR-alpha-Fc chimera may beselected from the group comprising:

-   -   I. a sequence having 90% or more identity to SEQ ID No. 2,    -   II. a sequence that is a truncated sequence of SEQ ID No. 2 or a        sequence having 90% or more identity to said truncated SEQ ID        No. 2 said sequence having at least 45 amino acids,    -   III. variants of sequences according to the yet aforementioned        items I. and II., with substitutions at one or more of the        following positions (numbering is adhered to SEQ ID. No. 1):        -   Ile-30, Glu-52, Ser-66, Ser-67, Asp-68, Leu-80, Ser-89,            His-162, Pro-169, Asp-173, Ile-188, Val-193, Lys-194,            Glu-213, Lys-304, Thr-320, His-334, Arg-340, Ile-373,            Lys-378, Ala-396, Ala-401, Thr-436, Thr-440, Ile-453,            Val-469, Ile-476, Ser-478, Asp-480, Ser-482, Arg-487.

A wild type chimera is a chimera of:

SEQ ID No. 2 (aa 24 to aa 524 of SEQ ID No. 1):QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRS E andSEQ ID No. 8 (6 amino acids which are a linkerbetween SEQ ID No. 1 and human Fc):LTVAGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

The biological activity of PDGF-type growth factors is determined as theinduction of cell proliferation in PDGF-sensitive cell lines such ashuman fibroblasts. The ability to inhibit this biological activity isdetermined as the degree by which induction of proliferation is reducedwhen PDGFs have been pre-incubated with the substance for 2 h at 37° C.,as compared to PDGFs alone. The degree of proliferation can be measuredin standard MTT assay as described previously (19). In addition oralternatively the direct binding of PDGF-type growth factors to thesoluble truncated or mutated version of PDGFR-alpha-Fc chimera (and thePDGFRalpha derived peptides) is measured via suitable techniques e.g.thermophorese using the Nanotemper technology; Biacore. and the like.

Also, subject matter of the present invention is a solublePDGFR-alpha-Fc chimera that is used for inhibiting HCMV entry in amethod of treatment in a subject that has been infected by HCMV or foruse in prophylaxis of HCMV infection in a subject that has not yet beeninfected by HCMV according to the present invention, wherein saidsoluble PDGFR-alpha-Fc chimera is administered to a pregnant woman whois infected by HCMV, or a congenitally HCMV-infected child, or a bonemarrow transplant recipient infected with HCMV, or a solid organtransplant recipients infected with HCMV. It may be also used in amethod of treatment in a subject that has been infected by HCMV, whereinsaid soluble PDGFR-alpha-Fc chimera is administered to said subject whois also HIV-infected.

In one embodiment a soluble PDGFR-alpha-Fc chimera according to thepresent invention comprises a sequence selected from the groupcomprising:

SEQ ID No. 3: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRE LKLVAPTLRSE,SEQ ID No. 4: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLG AENRELKLVAPTLRSE,SEQ ID No. 5: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNFFTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRE LKLVAPTLRSE,SEQ ID No. 6: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIP, SEQ ID No. 7:VYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIP.

In one embodiment of the present invention a soluble PDGFR-alpha-Fcchimera of the present invention comprises further a sequence of humanFc that is SEQ ID No. 8:

LTVAGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.

Subject matter of the present invention is a PDGFR-alpha derived peptidefor inhibiting HCMV entry that is for use in a method of treatment in asubject that has been infected by HCMV or for use in a methodprophylaxis of HCMV infection in a subject that has not yet beeninfected by HCMV, wherein said peptide is selected from a groupcomprising SEQ ID No. 9 (between 10 aa and 60 aa in length), SEQ ID No.10, SEQ ID No. 11, or SEQ ID NO: 12, or SEQ ID No. 13, or consists ofparts of the following sequences:

-   -   I. SEQ ID No. 9 that is VLEVSSASAAHTGLYTCYYNHTQTEENELE        GRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHN,    -   II. SEQ. ID No. 10, also referred to as IK40, that is        IKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMK,    -   III. SEQ ID No. 11, also referred as GD30, that is        GRHIYIYVPDPDVAFVPLGMTDYLVIVEDD),    -   IV. SEQ ID No. 12 (also referred to as GT40) that is        GRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTT,    -   V. SEQ ID No. 13 (also referred to as NV40) that is        NVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVV,    -   VI. a peptide fragment of SEQ ID No. 9, SEQ ID No. 10, SEQ ID        NO: 11, or SEQ ID No. 12, or SEQ ID No. 13, any of these having        at least 10 amino acids, and    -   VII. a variant of the yet aforementioned items I., to VI. that        exhibits at least 80% sequence identity to the peptide having        the sequence of SEQ ID No. 9, SEQ ID No. 10, SEQ ID NO: 11, or        SEQ ID No. 12, or SEQ ID No. 13, or a peptide that exhibits at        least 80% sequence identity to the peptide fragment of SEQ ID        No. 9, SEQ ID No. 10, SEQ ID NO: 11, SEQ ID No. 12, or SEQ ID        No. 13, having at least 10 amino acids.        any of these having at least 10 amino acids, and    -   VII. a variant of the yet aforementioned items I., to VI. that        exhibits at least 80% sequence identity to the peptide having        the sequence of SEQ ID No. 9, SEQ ID No. 10, SEQ ID NO: 11, or        SEQ ID No. 12, or SEQ ID No. 13, or a peptide that exhibits at        least 80% sequence identity to the peptide fragment of SEQ ID        No. 9, SEQ ID No. 10. SEQ ID NO: 11, SEQ ID No. 12, or SEQ ID        No. 13, having at least 10 amino acids.

Subject matter of the present invention is a PDGFR-alpha derived peptidefor inhibiting HCMV entry used for a method of treatment in a subjectthat has been infected by HCMV or for use in a method of prophylaxis ofHCMV infection in a subject that has not yet been infected by HCMVaccording to the present invention, wherein said peptide inhibits HCMVentry. In some embodiments, said PDGFR-alpha derived peptide is afragment derived from domain 1, domain 2, or domain 3 of PDGFR-alpha asexemplified by the peptides according to SEQ ID Nos. 9 to 13.

Subject matter of the present invention is a soluble PDGFR-alpha derivedpeptide for inhibiting HCMV entry used in a method of treatment in asubject that has been infected by HCMV or for use in a method ofprophylaxis of HCMV infection in a subject that has not yet beeninfected by HCMV according to the present invention, wherein saidpeptide is administered to a pregnant woman that is infected by HCMV ora congenitally HCMV-infected child, or a bone marrow transplantrecipient infected with HCMV or at risk of HCMV infection, or a solidorgan transplant recipient infected with HCMV or at risk with HCMVinfection. In some embodiments, said PDGFR-alpha derived peptide is afragment derived from domain 1, domain 2, or domain 3 of PDGFR-alpha asexemplified by the peptides according to SEQ ID Nos. 9 to 13.

Subject matter of the present invention are also delivery vectors fortransferring a nucleic acid sequence encoding a PDGFR-alpha derivedpeptide or fragment thereof suitable for inhibiting HCMV entry, whereinsaid nucleic acid comprises a signal sequence that enables the packingof said peptide or fragment thereof into vesicles, wherein the peptideor fragment is released from the cells to bind to HCMV and inhibitinfection of target cells. The object of the present invention is, thus,to provide delivery vectors for transferring a nucleic acid sequence toa cell in vitro, ex vivo or in vivo. Object of the invention is inparticular a vector-based therapy for treatment and/or prophylaxisand/or prevention of spreading in a host of HCMV infection withPDGFR-alpha derived peptides or fragments thereof. The inventivedelivery vectors comprising a nucleic acid encoding PDGFR-alpha derivedpeptides or fragments thereof shall transduce host cells, which arecapable of expressing the peptides and which are suitable for expressionof said peptides to thereby inhibiting HCMV infection, attachment,membrane fusion or propagation of the virus. This means as an examplethat said delivery vector may comprise a DNA sequence encoding aPDGFR-alpha peptide as defined herein and expresses the respectivepeptide(s) or fragment(s) thereof at a concentration that is sufficientto inhibit infections of target cells. In some embodiments, saidPDGFR-alpha derived peptide is a fragment derived from domain 1, domain2, or domain 3 of PDGFR-alpha as exemplified by the peptides accordingto SEQ ID Nos. 9 to 13.

The delivery vectors produced according to the present invention areuseful for the delivery of nucleic acids to cells in vitro, ex vivo, andin vivo. In particular, the delivery vectors can be advantageouslyemployed to deliver or transfer nucleic acids to animal, more preferablymammalian, cells.

Suitable vectors include viral vectors (e.g., retrovirus, lentivirus,alphavirus; vaccinia virus; adenovirus, adeno-associated virus, orherpes simplex virus), lipid vectors, polylysine vectors, syntheticpolyamino polymer vectors that are used with nucleic acid molecules,such as plasmids, and the like.

Any viral vector that is known in the art can be used in the presentinvention. Examples of such viral vectors include, but are not limitedto vectors derived from: Adenoviridae; Birnaviridae; Bunyaviridae;Caliciviridae, Capillovirus group; Carlavirus group; Carmovirus virusgroup; Group Caulimovirus; Closterovirus Group; Commelina yellow mottlevirus group; Comovirus virus group; Coronaviridae; PM2 phage group;Corcicoviridae; Group Cryptic virus; group Cryptovirus; Cucumovirusvirus group Family ([PHgr]6 phage group; Cysioviridae; Group Carnationringspot; Dianthovirus virus group; Group Broad bean wilt; Fabavirusvirus group; Filoviridae; Flaviviridae; Furovirus group; GroupGerminivirus; Group Giardiavirus; Hepadnaviridae; Herpesviridae;Hordeivirus virus group; Illarvirus virus group; Inoviridae;Iridoviridae; Leviviridae; Lipothrixviridae; Luteovirus group;Marafivirus virus group; Maize chlorotic dwarf virus group; icroviridae;Myoviridae; Necrovirus group; Nepovirus virus group; Nodaviridae;Orthomyxoviridae; Papovaviridae; Paramyxoviridae; Parsnip yellow fleckvirus group; Partitiviridae; Parvoviridae; Pea enation mosaic virusgroup; Phycodnaviridae; Picomaviridae; Plasmaviridae; Prodoviridae;Polydnaviridae; Potexvirus group; Potyvirus; Poxviridae; Reoviridae;Retroviridae; Rhabdoviridae; Group Rhizidiovirus; Siphoviridae;Sobemovirus group; SSV I-Type Phages; Tectiviridae; Tenuivirus;Tetraviridae; Group Tobamovirus; Group Tobravirus; Togaviridae; GroupTombusvirus; Group Tobovirus; Totiviridae; Group Tymovirus; and Plantvirus satellites. Protocols for producing recombinant viral vectors andfor using viral vectors for nucleic acid delivery can be found in(Ausubel et al., 1989) and other standard laboratory manuals (e.g.,Rosenzweig et al. 2007). Particular examples of viral vectors are thosepreviously employed for the delivery of nucleic acids including, forexample, retrovirus, lentivirus, adenovirus, adeno-associated virus(AAV) and other parvoviruses, herpes virus, and poxvirus vectors. Theterm “parvovirus” as used herein encompasses the family Parvoviridae,including autonomous parvoviruses, densoviruses and dependoviruses. Theterm AAV includes all vertebrate variants especially of human, primate,other mammalian, avian or serpentine origin. The autonomous parvovirusesinclude members of the genera Parvovirus, Erythrovirus, Bocavirus,Densovirus, Iteravirus, and Contravirus. Exemplary autonomousparvoviruses include, but are not limited to, minute virus of mice,bovine parvovirus, canine parvovirus, chicken parvovirus, felinepanleukopenia virus, feline parvovirus, goose parvovirus, HI parvovirus,muscovy duck parvovirus, bocavirus, bufavirus, tusavirus and B19 virus,and any other virus classified by the International Committee onTaxonomy of Viruses (ICTV) as a parvovirus. Other autonomousparvoviruses are known to those skilled in the art. See, e.g. (Berns etal. 2013).

In one embodiment of the invention said delivery vector comprises inaddition a recombinant adeno-associated virus (AAV) vector genome or arecombinant lentivirus genome.

In one particular embodiment of the invention said delivery vectorcomprises in addition a recombinant AAV vector, wherein preferably saidvector is a serotype of human or primate origin.

In one particular embodiment of the invention said delivery vectorcomprises in addition a recombinant adeno-associated virus (AAV) vectorgenome, wherein said vector is a human serotype vector selected from thegroup comprising serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, rh10, 11, 12,13, 14, serpentine AAV, ancestral AAV, or AAV capsid mutants derivedthereof, preferably but not exclusively of AAV serotype 1 or 2.

In one particular embodiment of the invention said delivery vector is asingle stranded AAV vector or a self-complimentary (or dimeric) duplexvector.

In one particular embodiment of the invention said delivery vector is adelivery vector as described above, wherein the DNA sequence encoding aPDGFR-alpha-derived peptide or fragment as defined herein is operativelylinked to expression control elements comprising a promoter and/orenhancer that produces sufficient expression of the gene product ofinterest to obtain a therapeutic effect.

For example, the encoding nucleic acid may be operably associated withexpression control elements, such as transcription/translation controlsignals, origins of replication, polyadenylation signals, and internalribosome entry sites (IRES), promoters, enhancers, and the like. It willfurther be appreciated that a variety of promoter/enhancer elements maybe used depending on the level and tissue-specific expression desired.The promoter/enhancer may be constitutive or inducible, depending on thepattern of expression desired. The promoter/enhancer may be native orforeign and can be a natural or a synthetic sequence. By foreign, it isintended that the transcriptional initiation region is not found in thewild-type host into which the transcriptional initiation region isintroduced. Promoter/enhancer elements that are functional in the targetcell or subject to be treated are most preferred. Mammalianpromoter/enhancer elements are also preferred. The promoter/enhancerelement may express the transgene constitutively or inducibly.

Exemplary constitutive promoters include, but are not limited to aBeta-actin promoter, a cytomegalovirus promoter, acytomegalovirus-enhancer/chicken beta-actin hybrid promoter, and a Roussarcoma virus promoter. Inducible expression control elements aregenerally employed in those applications in which it is desirable toprovide regulation over expression of the heterologous nucleic acidsequence(s). Inducible promoters/enhancer elements for gene deliveryinclude neuron-specific, brain-specific, muscle specific (includingcardiac, skeletal and/or smooth muscle), liver specific, bone marrowspecific, pancreatic specific, spleen specific, and lung specificpromoter/enhancer elements.

Other inducible promoter/enhancer elements include drug-inducible,hormone-inducible and metal-inducible elements, and other promotersregulated by exogenously supplied compounds, including withoutlimitation, the zinc-inducible metallothionein (MT) promoter; thedexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter;the T7 polymerase promoter system (see WO 98/10088); theecdysone-inducible insect promoter (No et al, 1996); thetetracycline-repressible system (Gossen and Bujard, 1992); thetetracycline-inducible system (Gossen et al., 1995); see also (Harvey etal., 1998); the RU486-inducible system (Wang, DeMayo et al., 1997);(Wang, Xu et al., 1997); and the rapamycin-inducible system (Magari etal., 1997).

In a particular embodiment of the invention the promoter and/or enhanceris selected from the group comprising constitutively active promoterse.g. CMV (cytomegalovirus immediate-early gene enhancer/promoter)- orCBA promoter (chicken beta actin promoter and human cytomegalovirus IEgene enhancer), or inducible promoters comprising Gene Switch,tet-operon derived promoter, preferably but not exclusively of humanorigin.

In a particular embodiment of the invention said delivery vector furthercomprises a posttranscriptional regulatory element, preferably thewoodchuck-hepatitis-virus-posttranscriptional-regulatory element. Otherpossible posttranscriptional regulatory elements are known to a personskilled in the art.

Subject of the present invention is furthermore a recombinant genetherapy vector comprising the foreign, therapeutic coding sequence,which is flanked by genetic elements for its expression and byvirus-specific cis elements for its replication, genome packaging,genomic integration etc. The said virus genome is encapsidated as virusparticle consisting of virus-specific proteins as in the case of AAV. Inthe case of lentivirus vectors the viral genome and virus-specificproteins, like reverse transcriptase and others are encapsidated intolentivirus capsids. These are enveloped by a lipid bilayer into whichvirus-specific proteins are embedded. Liposomes comprise the abovedescribed nucleotide sequences or entire DNA backbones including allregulatory elements of the gene therapy-, or delivery vector.

Examples of liposomes include DSPC(1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, DSPE-PEG2000(1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[amino(polyethyleneglycol)-2000], or DSPE-PEG2000-mal(1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[maleimide(polyethyleneglycol)-2000] or variants comprising sphingomyelin/cholesterol andphosphatidic acid.

In one particular embodiment of the invention said delivery vectorcomprises in addition a recombinant adeno-associated virus (AAV) vectorgenome and said recombinant AAV (rAAV) vector genome is encapsidated inan AAV capsid.

Adeno-associated viruses (AAV) have been developed as nucleic aciddelivery vectors. For a review, see (Muzyczka, 1992). AAV arehelper-dependent parvoviruses requiring a helper virus, typicallyadenovirus or herpesvirus for productive replication. AAV represent agrowing family of currently 14 naturally occurring serotypes of human orprimate origin. AAVs of other mammalian species, or of avian or insectorigin have been described (see Berns et al., 2013). The AAVs have smallicosahedral capsids, 18-26 nanometers in diameter and contain asingle-stranded DNA genome of 4-5 kilobases in length. AAV encapsidatesboth AAV DNA strands, either the sense or antisense DNA strand isincorporated into one virion. The AAV genome carries two major openreading frames encoding the genes rep and cap. Rep encodes a family ofoverlapping, nonstructural, regulatory proteins. In the best-studied AAVprototype strain, AAV2, the mRNAs for Rep78 and Rep68 are transcribedfrom the AAV p5 promoter (Stutika et al. 2015). Rep78/68 are requiredfor AAV transcription. AAV DNA replication, AAV integration into thehost cell genome and its rescue therefrom. Rep52 and Rep40 representN-terminally truncated versions of Rep78 and Rep68 transcribed from aseparate promoter, p19 and are required for encapsidation of the newlysynthesized AAV genome into preformed AAV capsids. These are formed bythe three cap gene-derived proteins, VP1, VP2, and VP3. The cap ORF alsoencodes AAP, an assembly-enhancing protein that does not form part ofthe capsid. The AAV ORFs are flanked by inverted terminal repeatsequences (ITRs) at either end of the genome. These vary in lengthbetween AAV serotypes, in AAV2 these comprise around 145 bp, the first125 bp thereof are capable of forming Y- or T-shaped duplex structures.The ITRs represent the minimal AAV sequences required in cis for DNAreplication, packaging, genomic integration and rescue. Only these haveto be retained in an AAV vector to ensure DNA replication and packagingof the AAV vector genome. Foreign genes flanked by AAV-ITRs will bereplicated and packaged into AAV capsids provided the AAV genes rep andcap are expressed in trans in the chosen packaging cell (Muzyczka,1992).

AAV are among the few viruses that can persist over months and years innon-dividing cells in vivo, including neurons, muscle, liver, heart andothers. Wildtype AAV2 has been shown to integrate its genome into thehost cell genome in a Rep78/68-dependent manner, with a preference forchromosomal loci with DNA sequence homology to the so-called Rep-bindingsite which forms part of the AAV-ITRs (Huser et al., 2014). In contrast,AAV vectors mostly persist as nuclear episomes. Devoid of the AAV genesrep and cap AAV vectors rarely integrate at all, and if so withoutgenomic preference (Huser et al., 2014). Nonetheless long-term AAVpersistence has been shown in non-dividing, postmitotic cells.

Generally, a recombinant AAV vector (rAAV) genome will only retain theinverted terminal repeat (ITR) sequence(s) so as to maximize the size ofthe transgene that can be efficiently packaged by the vector. Thestructural- and non-structural protein-coding sequences may be providedin trans, e.g., from a vector, such as a plasmid, by stably integratingthe respective genes into a packaging cell, or in a recombinant helpervirus such as HSV or baculovirus, as reviewed in (Mietzsch, Grasse etal., 2014). Typically, the rAAV vector genome comprises at least one AAVterminal repeat, more typically two AAV terminal repeats, whichgenerally will be at the 5′ and 3′ ends of the heterologous nucleotidesequence(s). The AAV ITR may be from any AAV including serotypes 1-14.Since AAV2-derived ITRs can be cross-packaged into virtually any AAVserotype capsids, AAV2 ITRs combined with AAV2 rep are mostly employed.The AAV terminal repeats need not maintain the wild-type terminal repeatsequence (e.g., a wild-type sequence may be altered by insertion,deletion, truncation or missense mutations), as long as the terminalrepeat mediates the desired functions, e.g., replication, viruspackaging, integration, and/or provirus rescue, and the like. The rAAVvector genome is generally between 80% to about 105% of the size of thewild-type genome and comprises an appropriate packaging signal as partof the AAV-ITR. To facilitate packaging into an AAV capsid, the entirevector genome is preferably below 5.2 kb, more preferably up to 4.8 kbin size to facilitate packaging of the recombinant genome into the AAVcapsid. So-called dimeric or self-complementary AAV vectors (dsAAV) weredeveloped that package double-stranded instead of single-stranded AAVgenomes (McCarty et al., 2001). These lead to enhanced AAV geneexpression, however at the price of reduced transgene capacity. Only upto 2 kb of foreign genes can be packaged, which is enough for smallgenes or cDNAs.

Any suitable method known in the art can be used to produce AAV vectorsexpressing the nucleic acids of this invention. AAV vector stocks can beproduced by co-transfection of plasmids for the ITR-flanked AAV vectorgenome expressing the transgene together with an AAV rep/cap expressingplasmid of the desired serotype and adenovirus-derived helper genes forAAV replication (Grimm et al., 2003; Xiao et al., 1998). AAV vectors canalso be produced in packaging cell lines of mammalian or insect originand/or in combination with recombinant helper viruses, such asadenovirus, herpes simplex virus (HSV), another member of theherpesvirus family, or baculovirus, as reviewed and discussed in(Mietzsch, Grasse et al., 2014).

Another embodiment of the present invention is a method of delivering anucleic acid to a cell of the, comprising contacting the cell with thedelivery vector or recombinant virus particle as described above underconditions sufficient for the DNA sequence to be introduced into thecell. The delivery vectors of the present invention provide a means fordelivering nucleic acid sequences into cells of a host to be treated.The delivery vectors may be employed to transfer a nucleotide sequenceof interest to a cell in vitro, e.g., to produce a polypeptide in vitroor for ex vivo gene therapy. The vectors are additionally useful in amethod of delivering a nucleotide sequence to a subject in need thereof.In this manner, the polypeptide may thus be produced in vivo in thesubject. The subject may be in need of the peptide because theproduction of the polypeptide in the subject may impart some therapeuticeffect, as a method of treatment or otherwise.

In one particular embodiment of the method of delivering a nucleic acidto a cell so that the PDGFR-alpha-derived peptide is produced andreleased from the cell.

In one particular embodiment of the method of delivering a nucleic acidto a cell of host, wherein the method comprises contacting the cell withthe recombinant virus particle or liposome as described above underconditions sufficient for the DNA sequence to be introduced into thecell. Conditions sufficient for the DNA sequence to be introduced intothe cell comprise the contacting of the AAV capsid to host cell surfacereceptors and coreceptors. AAV1 capsids bind to 2-3 sialic acid linkedto N-acetylgalactosamine, followed by 1-4-linked N-acetylglucosamine,whereas AAV2 capsids bind to heparin sulfate proteoglycan particularly6-O- and N-sulfated heparins on the cell surface (Mietzsch, Broecker etal., 2014). AAV coreceptors include FGFR-1, Integrin aVb5, hepatocytegrowth factor receptor (c-met) and a recently identified, universal AAVreceptor, AAVR necessary for transduction with AAV1, AAV2 and othersirrespective of the presence of specific glycans (Pillay et al., 2016).AAVR directly binds to AAV particles and helps trafficking to thetrans-Golgi network. In any case AAV vectors are expressed in the cellnucleus.

One embodiment of the invention is a delivery vector or recombinantvirus particle or liposome as described above for use as medicament.

One embodiment of the invention is a delivery vector or recombinantvirus particle or liposome as described above for use the preparation ofa medicament.

One embodiment of the invention is a method of treating a diseasedsubject in need of therapy by administering a delivery vector orrecombinant virus particle or liposome as described above.

The delivery of peptides is known in the art as can be derived fromstandard textbooks such as “Peptide and Protein Delivery”, AP, Chris vander Walle (Ed.). 1^(st) edition 2011.

Subject of the present invention is an anti-PDGFR-alpha antibody or aPDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffoldbinding to the HCMV binding region of PDGFR-alpha SEQ ID No. 4.

Subject of the present invention is an anti-PDGFR-alpha antibody or aPDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffoldbinding to the HCMV binding region of PDGFR-alpha SEQ ID No. 4 andinhibiting the binding of HCMV to PDGFR-alpha, wherein the inhibition ofbinding of HCMV to PDGFR-alpha is determined as follows:

Infectious cell free HCMV preparations (corresponding to a multiplicityof infection of 1) are pre-incubated with PDGFR-alpha-Fc chimera inabsence or presence of the anti-PDGFR-alpha antibody or a PDGFR-alphaantibody fragment or anti-PDGFR-alpha non-Ig scaffold (at variableconcentrations) for 2 h at 37° C. The pre-incubated mixture of HCMV,PDGFR-alpha-Fc chimera and anti-PDGFR-alpha antibody or a PDGFR-alphaantibody fragment or anti-PDGFR-alpha non-Ig scaffold is added to humanprimary fibroblasts at 0° C. Cells are incubated with the mixture for 2h at 0° C. The mixture of HCMV, PDGFR-alpha-Fc chimera andanti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment oranti-PDGFR-alpha non-Ig scaffold is then removed and replaced withfixation solution (80% acetone) at ambient temperature. After 5 min,acetone is replaced with phosphate buffered solution (PBS) and washedthree times with PBS. Bound PDGFR-alpha is detected byimmunofluorescence using fluorescence-labeled anti-human-IgG-Fcantibodies. The EC₅₀ is determined as the concentration of theanti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment oranti-PDGFR-alpha non-Ig scaffold (given in μg/ml) that reduces therelative fluorescence units per HCMV particle by 50% as compared toirrelevant control antibodies and wherein antibodies are regardedeffective if the ECs) in the assay described above is lower than 5μg/ml.

Subject matter of the present invention is also an anti-PDGFR-alphaantibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Igscaffold according to the present invention that is inhibiting HCMVentry.

Subject matter of the present invention is also an anti-PDGFR-alphaantibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Igscaffold according to the present invention for inhibiting HCMV entryfor use in a method of treatment in a subject that has been infected byHCMV or for use in a method of prophylaxis of HCMV infection in asubject that has not yet been infected by HCMV.

Subject matter of the present invention is an anti-PDGFR-alpha antibodyor a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffoldaccording to the present invention for inhibiting HCMV entry for use ina method of treatment in a subject that has been infected by HCMV or forprophylaxis of HCMV infection in a subject that has not yet beeninfected by HCMV, wherein said peptide is administered, and wherein saidanti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment oranti-PDGFR-alpha non-Ig scaffold is administered to a pregnant woman whois infected by HCMV, or a congenitally HCMV-infected child, or a bonemarrow transplant recipient infected with HCMV, or a solid organtransplant recipients infected with HCMV.

In one aspect of the invention said anti-PDGFR-alpha antibody or aPDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold ismonospecific. “Monospecific” means that said antibody or antibodyfragment or scaffold binds to one specific region encompassingpreferably at least 4, or at least 5 amino acids within the target.

An antibody according to the present invention is a protein includingone or more polypeptides substantially encoded by immunoglobulin genesthat specifically binds an antigen. The recognized immunoglobulin genesinclude the kappa, lambda, alpha (IgA), gamma (IgG₁, IgG₂, IgG₃, IgG₄),delta (IgD), epsilon (IgE) and mu (IgM) constant region genes, as wellas the myriad immunoglobulin variable region genes. Full-lengthimmunoglobulin light chains are generally about 25 Kd or 214 amino acidsin length. Full-length immunoglobulin heavy chains are generally about50 Kd or 446 amino acid in length. Light chains are encoded by avariable region gene at the NH₂-terminus (about 110 amino acids inlength) and a kappa or lambda constant region gene at the COOH-terminus.Heavy chains are similarly encoded by a variable region gene (about 116amino acids in length) and one of the other constant region genes.

The basic structural unit of an antibody is generally a tetramer thatconsists of two identical pairs of immunoglobulin chains, each pairhaving one light and one heavy chain. In each pair, the light and heavychain variable regions bind to an antigen, and the constant regionsmediate effector functions. Immunoglobulins also exist in a variety ofother forms including, for example, Fv, Fab, and (Fab′)₂, as well asbifunctional hybrid antibodies and single chains (e.g., Lanzavecchia etal., Eur. J. Immunol. 17:105, 1987; Huston et al., Proc. Natl. Acad.Sci. U.S.A., 85:5879-5883, 1988; Bird et al., Science 242:423-426, 1988;Hood et al., Immunology, Benjamin, N.Y., 2nd ed., 1984; Hunkapiller andHood, Nature 323:15-16, 1986).

An immunoglobulin light or heavy chain variable region includes aframework region interrupted by three hypervariable regions, also calledcomplementarity determining regions (CDR's) (see, Sequences of Proteinsof Immunological Interest, E. Kabat et al., U.S. Department of Healthand Human Services, 1983). As noted above, the CDRs are primarilyresponsible for binding to an epitope of an antigen. An immune complexis an antibody, such as a monoclonal antibody, chimeric antibody,humanized antibody or human antibody, or functional antibody fragment,specifically bound to the antigen.

Chimeric antibodies are antibodies whose light and heavy chain geneshave been constructed, typically by genetic engineering, fromimmunoglobulin variable and constant region genes belonging to differentspecies. For example, the variable segments of the genes from a mousemonoclonal antibody can be joined to human constant segments, such askappa and gamma 1 or gamma 3. In one example, a therapeutic chimericantibody is thus a hybrid protein composed of the variable orantigen-binding domain from a mouse antibody and the constant oreffector domain from a human antibody, although other mammalian speciescan be used, or the variable region can be produced by moleculartechniques. Methods of making chimeric antibodies are well known in theart, e.g., see U.S. Pat. No. 5,807,715. A “humanized” immunoglobulin isan immunoglobulin including a human framework region and one or moreCDRs from a non-human (such as a mouse, rat, or synthetic)immunoglobulin. The non-human immunoglobulin providing the CDRs istermed a “donor” and the human immunoglobulin providing the framework istermed an “acceptor.” In one embodiment, all the CDRs are from the donorimmunoglobulin in a humanized immunoglobulin. Constant regions need notbe present, but if they are, they must be substantially identical tohuman immunoglobulin constant regions, i.e., at least about 85-90%, suchas about 95% or more identical. Hence, all parts of a humanizedimmunoglobulin, except possibly the CDRs, are substantially identical tocorresponding parts of natural human immunoglobulin sequences. A“humanized antibody” is an antibody comprising a humanized light chainand a humanized heavy chain immunoglobulin. A humanized antibody bindsto the same antigen as the donor antibody that provides the CDRs. Theacceptor framework of a humanized immunoglobulin or antibody may have alimited number of substitutions by amino acids taken from the donorframework. Humanized or other monoclonal antibodies can have additionalconservative amino acid substitutions, which have substantially noeffect on antigen binding or other immunoglobulin functions. Exemplaryconservative substitutions are those such as GLY, ALA; VAL, ILE, LEU;ASP, GLU; ASN, GLN; SER, THR; LYS, ARG; AND PIE, TYR. Humanizedimmunoglobulins can be constructed by means of genetic engineering(e.g., see U.S. Pat. No. 5,585,089). A human antibody is an antibodywherein the light and heavy chain genes are of human origin. Humanantibodies can be generated using methods known in the art. Humanantibodies can be produced by immortalizing a human B cell secreting theantibody of interest Immortalization can be accomplished, for example,by EBV infection or by fusing a human B cell with a myeloma or hybridomacell to produce a trioma cell. Human antibodies can also be produced byphage display methods (see, e.g., Dower et al., PCT Publication No.WO91/17271; McCafferty et al., PCT Publication No. WO92/001047; andWinter, PCT Publication No. WO92/20791), or selected from a humancombinatorial monoclonal antibody library (see the Morphosys website).Human antibodies can also be prepared by using transgenic animalscarrying a human immunoglobulin gene (for example, see Lonberg et al.,PCT Publication No. WO93/12227; and Kucherlapati, PCT Publication No.WO91/10741).

In a preferred embodiment of the invention, the antibody format isselected from the group comprising Fv fragment, scFv fragment, Fabfragment, scFab fragment, (Fab)₂ fragment and scFv-Fc-fusion protein. Inanother preferred embodiment of the invention, the antibody format isselected from the group comprising scFab fragment, Fab fragment, scFvfragment and bioavailability optimized conjugates thereof, such asPEGylated fragments.

Non-Ig scaffolds may be protein scaffolds and may be used as antibodymimics as they are capable to bind to ligands or antigenes. Non-Igscaffolds may be selected from the group comprising tetranectin-basednon-Ig scaffolds (e.g. described in US 2010/0028995), fibronectinscaffolds (e.g. described in EP 1266 025; lipocalin-based scaffolds((e.g. described in WO 2011/154420); ubiquitin scaffolds (e.g. describedin WO 2011/073214), transferring scaffolds (e.g. described in US2004/0023334), protein A scaffolds (e.g. described in EP 2231860),ankyrin repeat based scaffolds (e.g. described in WO 2010/060748),microproteins, preferably microproteins forming a cystine knot)scaffolds (e.g. described in EP 2314308), Fyn SH3 domain based scaffolds(e.g. described in WO 2011/023685) EGFR-A-domain based scaffolds (e.g.described in WO 2005/040229) and Kunitz domain based scaffolds (e.g.described in EP 1941867).

The anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment oranti-PDGFR-alpha non-Ig scaffold according to the present inventionexhibits an affinity towards human PDGFR-alpha in such that affinityconstant is greater than 10⁻⁷ M, preferred 10⁻⁸ M, more preferredaffinity is greater than 10⁻⁹ M, most preferred higher than 10⁻¹⁰ M. Aperson skilled in the art knows that it may be considered to compensatelower affinity by applying a higher dose of compounds and this measurewould not lead out-of-the-scope of the invention. The affinity constantsmay be determined according to the method as described previously (40).

Subject of the present invention are also pharmaceutical formulationscomprising a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derivedpeptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibodyfragment or anti-PDGFR-alpha non-Ig scaffold.

Subject matter of the present invention encompass also methods fortreatment of a subject that has been infected by HCMV or for prophylaxisof HCMV infection in a subject that has not yet been infected by HCMV,wherein a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derivedpeptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibodyfragment or anti-PDGFR-alpha non-Ig scaffold is administered to asubject in need thereof.

The compounds of the present invention exhibit certain advantages, allof them, in particular peptide and fusion protein and binder (antibody),are effective against various HCMV strains.

The compounds of the present invention, peptide and fusion protein andbinder (antibody), can inhibit HCMV infection of various cell types. Ina particular embodiment of the invention, a Fc-PDGFRα fusion proteinbinds to and neutralizes cell-free HCMV particles at an EC₅₀ of 10-50ng/ml. Treated particles show both reduced attachment to and reducedfusion with cells. In line with this result, Fc-PDGFRα was alsoeffective when applied post-attachment.

The compounds of the present invention are in particular potentinhibitors of HCMV entry into both fibroblasts and endothelial cells.The compounds of the present invention may lead to lesser side effectsduring treatment in a subject. Further, the risk of developingresistance against treatment is lower when administering the compoundsof the present invention in the methods of treatment in accordance ofthe instant invention. When using the compounds of the presentinvention, the risk of interference with intracellular pathways isgreatly reduced.

The compounds of the present invention are fully active at lowerconcentrations and are thus promising regarding the ratio of desired andadverse effects. Thus, an antiviral effect can be expected at doses thatwould not significantly bind and sequester the natural ligand, thuslimiting unwanted effects. Thus, the compounds of the present inventioncan be applied even in pregnant woman.

Considering their therapeutic application, the compounds of the presentinvention, in particular Fc-PDGFRα and PDGFRα-derived peptides, mayoffer a number of advantages: (i) they are host-derived and thereforeassumed to be non-immunogenic, (ii) an additive effect with theestablished anti-HCMV drugs can be expected due to the different modesof action; (iii) they are equally effective against infection offibroblasts and endo-/epithelial cells and (iv) resistance conferringmutations would most likely affect the entry potential of the virus andhence reduce viral fitness.

With the above context, further subject matter of the instant inventioncan be derived from the consecutively numbered embodiments below:

-   1. Soluble PDGFR-alpha-Fc chimera for inhibiting HCMV entry for use    in a method of treatment in a subject that has been infected by HCMV    or for use in a method of prophylaxis of HCMV infection in a subject    that has not yet been infected by HCMV, wherein said soluble    PDGFR-alpha-Fc chimera comprises a PDGFR-alpha sequence selected    from the group comprising:

I. SEQ ID No. 2 (amino acids 24 to amino acids 524 of SEQ ID No. 1):QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTLPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE,

-   -   II. a sequence having 90% or more identity to SEQ ID No. 2,    -   III. a sequence with at least 45 amino acids that is a truncated        sequence of SEQ ID No. 2 or a sequence having 90% or more        identity to said truncated SEQ ID No. 2,    -   IV. variants of sequences according to items I., II., III. with        substitutions at one or more of the following positions        (numbering adhered to SEQ ID. No. 1): Ile-30, Glu-52, Ser-66,        Ser-67, Asp-68, Leu-80, Ser-89, His-162, Pro-169, Asp-173,        Ile-188, Val-193, Lys-194, Glu-213, Lys-304, Thr-320, His-334,        Arg-340, Ile-373, Lys-378, Ala-396, Ala-401, Thr-436, Thr-440,        Ile-453, Val-469, Ile-476, Ser-478, Asp-480, Ser-482, Arg-487.

-   2. Soluble PDGFR-alpha-Fc chimera for inhibiting HCMV entry for use    in a method of treatment in a subject that has been infected by HCMV    or for use in a method of prophylaxis of HCMV infection in a subject    that has not yet been infected by HCMV according to embodiment 1,    wherein said soluble PDGFR-alpha-Fc chimera inhibits HCMV entry.

-   3. Soluble PDGFR-alpha-Fc chimera for inhibiting HCMV entry for use    in a method of treatment in a subject that has been infected by HCMV    or for use in a method of prophylaxis of HCMV infection in a subject    that has not yet been infected by HCMV according to embodiment 1 or    2, wherein said soluble PDGFR-alpha-Fc chimera has at least one of    the following mutations or deletions within SEQ ID No. 2 (numbering    adhered to SEQ ID. No. 1):    -   i. Deletion of aa 150-189,    -   ii. Deletion of an 150-234,    -   iii. Deletion of aa 150-290,    -   iv. Deletion of aa 150-524,    -   v. Deletion of aa 24-100 and deletion of an 150-234.    -   vi. SEQ ID No. 2 having at least one point mutation in at least        one of the protein regions as specified in the above items i.,        ii., iii., iv., v.

-   4. Soluble PDGFR-alpha-Fc chimera for inhibiting HCMV entry for use    in a method of treatment in a subject that has been infected by HCMV    or for use in a method of prophylaxis of HCMV infection in a subject    that has not yet been infected by HCMV according to embodiment 3,    wherein said soluble PDGFR-alpha-Fc chimera inhibits HCMV entry and    shows reduced ability to inhibit the biological activity of    PDGF-type growth factors as compared to the inhibitory effect of    wild type chimeras as defined in embodiment 1.

-   5. Soluble PDGFR-alpha-Fc chimera for inhibiting HCMV entry for use    in a method of treatment in a subject that has been infected by HCMV    or for use in a method of prophylaxis of HCMV infection in a subject    that has not yet been infected by HCMV according to any of    embodiments 1 to 4, wherein said soluble PDGFR-alpha-Fc chimera is    administered to a pregnant woman who is infected by HCMV, or a    congenitally HCMV-infected child, or a bone marrow transplant    recipient infected with HCMV, or a solid organ transplant recipients    infected with HCMV.

-   6. Soluble PDGFR-alpha-Fc chimera of any of the preceding    embodiments, comprising a sequence selected from the group    comprising:

I. SEQ ID No. 3: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE, II. SEQ ID No. 4:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIFCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE, III. SEQ ID No. 5:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTEIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE, IV. SEQ ID No. 6:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIP, V. SEQ ID No. 7:YYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAI IP.

-   7. Soluble PDGFR-alpha-Fc chimera of any of the preceding    embodiments, further comprising a sequence of human Fc that is SEQ    ID No. 8:

LTVAGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.

-   8. PDGFR-alpha derived peptide for inhibiting HCMV entry for use in    a method of treatment in a subject that has been infected by HCMV or    for use in a method of prophylaxis of HCMV infection in a subject    that has not yet been infected by HCMV, wherein said peptide is    selected from a group comprising SEQ ID No. 9 (between 10 aa and 60    aa in length), or SEQ ID No. 10, or SEQ ID No. 11, or SEQ ID No. 12,    or SEQ ID No. 13, or that consists of parts of the following    sequence:    -   i) SEQ ID No. 9 that is        VLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPL        GMTDYLVIVEDDDSAIIPCRTTDPETPVTLHN,    -   ii) SEQ ID No. 10: IKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMK,    -   ii) SEQ ID No. 11: GRHIYIYVPDPDVAFVPLGMTDYLVIVEDD,    -   iv) SEQ ID No. 12: GRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTT,    -   v) SEQ ID No. 13: NVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVV,    -   vi) a peptide fragment of SEQ ID No. 9 or SEQ ID No. 10, or SEQ        ID No. 11, or SEQ ID No. 12, or SEQ ID No. 13, any of them        having at least 10 amino acids, and    -   vii) a variant of the above items i). to vi). that exhibits at        least 80% sequence identity to the peptide having the sequence        of SEQ ID No. 9, or that exhibits at least 80% sequence identity        to the peptide having the sequence of SEQ ID No. 10, or that        exhibits at least 80% sequence identity to the peptide having        the sequence of SEQ ID No. 11, or that exhibits at least 80%        sequence identity to the peptide having the sequence of SEQ ID        No. 12, or that exhibits at least 80% sequence identity to the        peptide having the sequence of SEQ ID No. 13 or that exhibits at        least 80% sequence identity to the peptide fragments of SEQ ID        No. 9, SEQ ID No. 10, SEQ ID No. 11, or SEQ ID No. 12, or SEQ ID        No. 13, any of them having at least 10 amino acids.-   9. PDGFR-alpha derived peptide for inhibiting HCMV entry for use in    a method of treatment in a subject that has been infected by HCMV or    for use in a method of prophylaxis of HCMV infection in a subject    that has not yet been infected by HCMV according to embodiment 8,    wherein said peptide inhibits HCMV entry.-   10. Soluble PDGFR-alpha derived peptide for inhibiting HCMV entry    for use in a method of treatment in a subject that has been infected    by HCMV or for use in a method of prophylaxis of HCMV infection in a    subject that has not yet been infected by HCMV according to any of    embodiments 8 or 9, wherein said peptide is administered to a    pregnant woman that is infected by HCMV or a congenitally    HCMV-infected child, or a bone marrow transplant recipient infected    with HCMV or at risk of HCMV infection, or a solid organ transplant    recipients infected with HCMV or at risk with HCMV infection.-   11. Anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or    anti-PDGFR-alpha non-Ig scaffold binding to the HCMV binding region    of PDGFR-alpha SEQ ID No. 4.-   12. Anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or    anti-PDGFR-alpha non-Ig scaffold according to embodiment 11,    inhibiting the binding of HCMV to PDGFR-alpha, wherein the    inhibition of the binding of HCMV to PDGFR-alpha is determined as    follows:    -   Infectious cell free HCMV preparations (corresponding to a        multiplicity of infection of 1) are pre-incubated with        PDGFR-alpha-Fc chimera in absence or presence of the        anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or        anti-PDGFR-alpha non-Ig scaffold (at variable concentrations)        for 2 h at 37° C.,    -   The pre-incubated mixture of HCMV, PDGFR-alpha-Fc chimera and        anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or        anti-PDGFR-alpha non-Ig scaffold is added to human primary        fibroblasts at 0° C.,    -   Cells are incubated with the mixture for 2 h at 0° C.    -   The mixture of HCMV, PDGFR-alpha-Fc chimera and anti-PDGFR-alpha        antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha        non-Ig scaffold is then removed and replaced with fixation        solution (80% acetone) at ambient temperature,    -   After 5 min, acetone is replaced with phosphate buffered        solution (PBS) and washed three times with PBS,    -   Bound PDGFR-alpha is detected by immunofluorescence using        fluorescence-labeled anti-human-IgG-Fc antibodies,    -   The EC50 is determined as the concentration of the        anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or        anti-PDGFR-alpha non-Ig scaffold (given in μg/ml) that reduces        the relative fluorescence units per HCMV particle by 50% as        compared to irrelevant control antibodies, and wherein    -   antibodies are regarded effective if the EC₅₀ in the assay        described above is lower than 5 μg/ml.-   13. Anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or    anti-PDGFR-alpha non-Ig scaffold according to embodiment 11 or 12    inhibiting HCMV entry.-   14. Anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or    anti-PDGFR-alpha non-Ig scaffold according to any of embodiments 11    to 13 for inhibiting HCMV entry for use in a method of treatment in    a subject that has been infected by HCMV or for use in a method of    prophylaxis of HCMV infection in a subject that has not yet been    infected by HCMV.-   15. Anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or    anti-PDGFR-alpha non-Ig scaffold according to any of embodiments 11    to 14 for inhibiting HCMV entry for use in a method of treatment in    a subject that has been infected by HCMV or for use in a method of    prophylaxis of HCMV infection in a subject that has not yet been    infected by HCMV, wherein said peptide is administered, and wherein    said anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or    anti-PDGFR-alpha non-Ig scaffold is administered to a pregnant woman    who is infected by HCMV, or a congenitally HCMV-infected child, or a    bone marrow transplant recipient infected with HCMV, or a solid    organ transplant recipients infected with HCMV.

Sequence Listing SEQ ID No. 1 (PDGFR-alpha (ISOFORM 1):   10           20           30          40          50MGTSHPAFLV LGCLLTGLSL ILCQLSLPSI LPNENEKVVQ LNSSFSLRCF   60          70           80          90         100GESEVSWQYP MSEEESSDVE IRNEENNSGL FVTVLEVSSA SAAHTGLYTC  110         120          130         140         150YYNHTQTEEN ELEGRHIYIY VPDPDVAFVP LGMTDYLVIV EDDDSAIIPC   160         170         180         190         200RTTDPETPVT LHNSEGVVPA SYDSRQGFNG TFTVGPYICE ATVKGKKFQT   210         220         230         240         250IPFNVYALKA TSELDLHMEA LKTVYKSGET IVVTCAVFNN EVVDLQWTYP  260          270          280         290        300GFVKCKGITM LEEIKVPSIK LVYTLTVPEA TVKDSGDYEC AARQATREVK  310         320           330        340         350EMKKVTISVH EKGFIEIKPT FSQLEAVNLH EVKHFVVEVR AYPPPRISWL  360          370          380         390        400KNNLTLIENL TEITTDVEKI QEIRYPSKLK LIRAKEEDSG HYTIVAQNED  410          420         430         440         450AVKSYTFELL TQVPSSILDL VDDHHGSTCG QTVRCTAEGT PIPDIEWMIC  460         470          480          490        500KDIKKCNNET SWTILANNVS NIITEIHSRD RSTVEGRVTF AKVEETIAVR  510         520         530         540          550CLAKNLLGAE NRELKLVAPT LRSELTVAAA VLVLLVIVII SLIVLVVIWK  560          570          580         590        600QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFFR DGLVLGRVLG  610         620         630          640         650SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH   660         670          680         690        700LGPHLNIVNL LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFLSHHPEK  710           720          730        740        750PKKELDIFGL NPADESTRSY VILSFENNGD YMDMKQADTT QYVPMLERKE  760          770         780         790         800VSKYSDIQRS LYDRPASYKK KSMLDSEVKN LLSDDNSEGL TLLDLLSFTY  810         820         830          840         850QVARGMEFLA SKNCVHRDLA ARNVLLAQGK IVKICDFGLA RDIMHDSNYV   860        870          880         890         900SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM  910          920         930         940         950VDSTFYNKIK SGYRMAKPDH ATSEVYEIMV KCWNSEPEKR PSFYHLSEIV  960         970           980         990       1000ENLLPGQYKK SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL  1010       1020         1030        1040        1050KDWEGGLDEQ RLSADSGYII PLPDIDPVPE EEDLGKRNRH SSQTSEESAI  1060                          1070              1080ETGSSSSTFI KREDETIEDI DMMDDIGIDS SDLVEDSFLSEQ ID No. 2 (i.e. aa 24 - aa 524 of SEQ ID No. 1):QLSLPSI LPNENEKVVQ LNSSFSLRCF GESEVSWQYP MSEEESSDVE IRNEENNSGLFVTVLEVSSA SAAHTGLYTC YYNHTQTEEN ELEGRHIYIY VPDPDVAFVPLGMTDYLVIV EDDDSAIIPC RTTDPETPVT LHNSEGVVPA SYDSRQGFNGTFTVGPYICE ATVKGKKFQT IPFNVYALKA TSELDLHMEA LKTVYKSGETIVVTCAVFNN EVVDLQWTYP GEVKGKGITM LEEIKVPSTK LVYTLTVPEATVKDSGDYEC AARQATREVK EMKKVTISVH EKGFIEIKPT FSQLEAVNLHEVKHFVVEVR AYPPPRISWL KNNLTLIENL TEITTDVEKI QEIRYRSKLKLIRAKEEDSG HYTIVAQNED AVKSYTFELL TQVPSSILDL VDDHHGSTGGQTVRCTAEGT PLPDIEWMIC KDIKKCNNET SWTILANNVS NIITEIHSRDRSTVEGRVTF AKVEETIAVR CLAKNLLGAE NRELKLVAPT LRSESEQ ID No. 3 (Deletion of IgG-like loop 2; i.e. deletionof aa 150 to aa 189 of SEQ ID No. 2):QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEEN ELEGRHIYIY VPDPDVAFVP LGMTDYLVIVEDDDSAIIPEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNHTEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSESEQ ID No. 4 (Deletion of IgG-like loop 2 till loop 3; i.e.deletion of aa 150 - aa 234 of SEQ ID No. 2):QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKFITSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKL VAPTLRSESEQ ID No. 5 (Deletion of IgG-like loops 2 and 3; i.e.deletion of aa 150 - aa 290 of SEQ ID No. 2):QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPAARQATREVKEMKKVTISVHEKGFIEIKPTPSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELK LVAPTLRSESEQ ID No. 6 (Deletion of the ECD excluding Domain 1; i.e.deletion of aa 150 - aa 524 of SEQ ID No. 2):QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVI VEDDDSAIIPSEQ ID No. 7 (Deletion of the ECO excluding aa 101-149; i.e.deletion of aa 24 - aa 100 and deletion of aa 150 - aa 234of SEQ ID No. 2): YYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPSEQ ID No. 8: LTVAGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGKSEQ ID No. 9: VLEVSSASAAHTGLYTCYYNHTQTEENELEGRHJYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHN SEQ ID No. 10:IKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMK SEQ ID No. 11:GRHIYIYVPDPDVAFVPLGMTDYLVIVEDD SEQ ID No. 12:GRHIYIYVPDPDVAFVPEGMTDYLVIVEDDDSAIIPCRTT SEQ ID No. 13:NVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVV

EXAMPLES Example 1

Cells and Viruses: Primary human foreskin fibroblast (HFFs) werepropagated in MEM (plus GlutaMaxx; Gibco) supplemented with 5% fetalcalf serum (FCS), 100 μg/ml gentamycin and 0.5 ng/ml basic fibroblastgrowth factor. During experiments the cells were kept in maintenancemedium without growth factor. Conditionally immortalized humanendothelial cells (HEC-LTT, short HEC) (25, 28), were proliferated onvessels coated with 0.1% gelatin in endothelial cells growth medium(bullet kit; Lonza) with 2 μg/ml doxycycline. For experiments, the HECswere withdrawn from doxycycline for 24 hours to control the cell numbersof this otherwise fast dividing cell line. The efficiently transfectablehybrid endothelial cell line EA.hy926 (ATCC: CRL-2922; Edgell 1983) wasexpanded in DMEM (life technologies) plus 10% FCS.

The HCMV strains TB40/E and TB40/F were isolated from the same patient.TB40/E was propagated on endothelial cells and is highlyendotheliotropic, whereas TB40/F was kept on fibroblast and isnon-endotheliotropic (Sinzger 1999). AD169 (Rowe 1956 Plotkin 1975) andTowne (Plotkin 1975) are widely used HCMV strains, but lack thepentameric complex and are therefore non-endotheliotropic. VR1814(Revello 2001), VHL/E (Waldman 1991) and Merlin (Davison 2003) representendotheliotropic HCMV strains. TB40-BAC_(KL7)-UL32EGFP-UL100mCherry isan endotheliotropic descendant of TB40/E that was labelled to allowdifferentiation between enveloped and non-enveloped virus capsids(Sampaio 2013).

TB40-BAC4 is a highly endotheliotropic BACmid based on TB40/E (Sinzger2008) and BAC4UL74stop is an (yet unpublished) BAC4 mutant in which M7and K12 of pUL74 were changed to stop codons, resulting in loss ofexpression of pUL74 (gO). Virus stocks of TB40 variants, AD169, Towne,VHL/E and VR1814 were harvested from infected HFFs day 5 to 7 postinfection (p.i.). Supernatants were cleared from cells and large celldebris by centrifugation at 2,700 g for 10 min before storage at −80° C.Cleared UL74stop supernatants were 50 fold concentrated byultracentrifugation at 70,000 g for 70 min. The luciferase reportervirus contains a Gaussia expression cassette under control of the majorimmediate early promoter, therefore the luciferase is expressed with thesame kinetics as the immediate early proteins of HCMV (10). Virus stocksof the Gaussia luciferase reporter virus were first cleared and thentwice ultracentrifuged at 23000 g for 70 min to remove Luciferase thatis secreted along with the virus particles.

Example 2

Antiviral drugs, chimeric receptor mokcules and PDGFRα-derived peptides:All recombinant Fc-fusion proteins used in these studies were obtainedfrom R&D: PDGFR-alpha-Fc (6765-PR-050), PDGFRβ-Fc (385-PR-100), EGFR-Fc(344-ER-050). The 40 amino acid long peptides based on human PDGFRαisotype 1 extracellular domain were obtained from Phtdpeptides,Shanghai, China. All peptides were dissolved to a final concentration of1 mmol/A. Depending on their physiochemical properties either water,ammonium carbonate, dimethyl sulfoxide or acetic acid were used assolvents.

Example 3

Knockdown of protein expression by siRNA: For reverse transfection ofsiRNAs, cells were seeded at a density of 10,000 per well. As a negativecontrol the inventors used siGenome non-targeting pool #2 (Dharmacon),as a positive control served a highly efficient IE siRNA (Hochdorfer2016). Targets were knocked down with pools of four different siRNAs(siGenome Dharmacon). For each transfection using Lipofectamin RNAiMAX(Life Technologies) a final concentration of 50 nM was applied. 48 hpost transfection HCMV TB40/E was added to the cells at a multiplicityof 0.5 to 1. Infection was allowed for 1 day before cells were fixed andstained for viral immediate early antigens.

Example 4

Inhibition of infection: For testing the inhibitory effect of antiviralsor fusion proteins on HCMV, the respective inhibitors were diluted inMEM and mixed with infectious supernatants, the mixtures were incubatedfor 2 h at 37° C. before addition to the cells. For fibroblast infectionthe virus-inhibitor mixture was incubated on the cells for about 24 h.If endothelial cells were included in the experiment, all cells weresupplied with their respective maintenance media after 2 h, and furtherincubated for 22 h.

Example 5

Determination of infection efficiencies: Infection efficiencies weredetermined by immunofluorescence staining for viral proteins. Forfixation and permeabilization the cells were incubated with 80% acetonefor 5 min. For HCMV infected cells the immediate early proteinspUL122/123 were detected with a mouse monoclonal (clone E13, Argene) andvisualized using a Cy3 conjugated goat anti-mouse secondary antibody(Jackson Immuno Research). HSV infected cultures were stained 6 h postinfection for ICP0 using a mouse monoclonal (clone 11060, Santa Cruz)and goat anti-mouse AF488 (life technologies). DAPI was used to locatenuclei. Infection rates were determined by counting the number of cellnuclei positive for the respective viral protein, as well as the totalnumber of nuclei per image. For each condition three images wereevaluated.

For screening the PDGFRα peptides for their neutralizing capacity arecently developed Gaussia-Luciferase-Assay was utilized (10). TheGaussia luciferase is secreted into the cell culture supernatants,therefore it is not necessary to fix the cells and instead a sample ofthe Gaussia containing supernatant is taken and mixed with the substratecoelenterazine (PjK) at a final concentration of 0.2 μg/ml. Theresulting light emission was detected at 495 nm. For all obtained valuesbackground signals were subtracted and neutralization efficiency wasdetermined relative to the control samples which contained only virus,no peptide.

Example 6

Quantification of adsorption and penetration: To distinguish betweenadsorption and penetration of viral particles the inventors made use ofdual fluorescent HCMV TB40-BAC_(K)0.7-UL32EGFP-UL100mCherry (Sampaio2013). HFFs and HECs were seeded at a density of 40,000 cells per wellon gelatin-coated IBIDI plates. Overnight produced cell-free infectioussupernatant of the fluorescent virus was pre-incubated with PDGFR-Fcsfor 2 h at 37° C. Before addition of the mixture the cells werepre-incubated with MEM for 30 min. Penetration of virus particles whichhad been pre-incubated for 2 h with 500 ng/ml of Fc-fusion protein, wasallowed for 2 h at 37° C. After fixation with acetone, the EGFP signalof pUL32-EGFP was enhanced using mouse-anti-GFP (clone 3E6, Invitrogen)and Alexa488-anti-mouse (Life Technologies). DAPI(4′,6-diamidino-2-phenylindole) was added to mark the cell nuclei. Thenumber of mCherry and EGFP positive particles which are enveloped wascompared to the number of particles which were only green per cell.These EGFP-mCherry double positive particles have lost theirUL100mCherry containing envelope, presumably by fusion with cellularmembranes.

Example 7

Analysis of post adsorption inhibitory effects: For the analysis of postadsorption inhibition, HFFs were seeded at a density of 40,000 per wellon IBIDI plates and incubated for 1 day before infection. Infectioussupernatants of TB40E which were produced within 24 hours were clearedby centrifugation. Two identical plates were treated as follows: Cellsand virus dilutions were precooled on ice for 15 min before attachmentof the virus was allowed on ice for 1 h. The virus containing medium wasexchanged by pre-cooled MEM with or without 200 ng/ml PDGFR-alpha-Fc.After 2 h incubation of the inhibitor with the cells on ice, one platewas directly shifted to 37° C., whereas the other cells were treatedwith pre-warmed 50% PEG (Roche) for 30 sec. The PEG was washed off byfive times washing with pre-warmed PBS. Supplied with pre-warmed MEMcontaining again 200 ng/ml PDGFR-alpha-Fc, the cells were then incubatedat 37° C. After 2 h incubation the medium was exchanged on PEG-treatedand untreated cells and infection was allowed to proceed for 24 h beforeinfection efficiencies were assessed by immediate early staining.Efficient PEG fusion was controlled visually by detection of syncytia.

Example 8 Binding of Chimeric Receptors to HCMV Particles:

To assess the binding of Fc-Proteins to virus particles, HFFs wereseeded at a density of 40,000 cells per well on IBIDI plates 1 day priorto infection. Virus preparations were pre-incubated with Fc-fusionproteins at a final concentration of 500 ng/ml for 2 h at 37° C. Thevirus/Fc-protein mixtures were incubated with the cells for 1.5 h onice. Before fixation with 80% acetone, the cells were washed once withMEM. For staining of viral particles mouse hybridoma recognizing theabundant viral protein pp150 (generously provided by W. Britt, Sanchez2000) used. As a secondary antibody goat anti-mouse Cy3 (Jackson ImmunoResearch was used. Visualization of bound Fc-proteins was achieved byapplying anti-human Alexa488 (Invitrogen). For better orientation, cellnuclei were stained with DAPI. For quantification of PDGFR-alpha-Fcbinding to HCMV particles, the grey values of 100 particles percondition were quantified using AxioVision Software (Zeiss).

Example 9 Knockdown of PDGFR-Alpha Prevents HCMV Infection ofFibroblasts but not of Endothelial Cells

Two cellular growth factor receptor molecules, PDGFR-alpha and EGFR havebeen reported to promote HCMV infection in fibroblasts (33, 39).However, only fibroblast-restricted virus strains lacking the pentamericcomplex were used in those analyses, and in subsequent studies theirrelevance for HCMV infection was questioned (21, 35). As we aimed atexploring the potential of these molecules to serve as a basis for thedevelopment of HCMV entry inhibitors, the first step was to confirmtheir contribution to HCMV infection. To address the diverse entrypathways of HCMV the inventors applied a virus strain expressing bothgH/gL complexes on two model cell types representing the restrictedtropism (fibroblasts) or the extended tropism (endothelial cells).

Using an siRNA approach, the respective growth receptor was knocked down2 days before infection with HCMV strain TB40/E at an MOI of 1. Cellstreated with non-targeting siRNAs served as negative controls whilecells in which viral IE RNAs were knocked down served as positivecontrols. One day after infection, cell cultures were fixed, viral IEantigens were immunostained, and the fraction of IE-antigen-positivecells was determined. In each of three experiments, the relativeinfection efficiency as compared to the non-targeting control wasdetermined. As expected, knockdown of viral IE RNAs partially reducedthe infection efficiency. Knockdown of PDGFR-alpha almost completedprevented HCMV infection of fibroblasts whereas it had no inhibitoryeffect in endothelial cells (FIG. 1). Knockdown of EGFR did not reduceinfection efficiencies in any of the cell types.

In line with these results PDGFR-alpha was only found on the surface offibroblasts but not on endothelial cells in immunofluorescencestainings, and surface expression in fibroblasts was suppressed tolevels below the detection limit when they were treated with therespective siRNAs (data not shown).

In conclusion, of the two growth factor receptor molecules that hadpreviously been reported to promote HCMV entry, only the contribution ofPDGFR-alpha was confirmed in the present experimental setting.

Example 10

Pretreatment of HCMV with a Soluble PDGFR-Fc Chimera Inhibits Infectionof Fibroblasts and Endothelial Cells

The strong dependence of HCMV infection on expression of PDGFR-alphasuggested that viral particles interacted physically with this cellulargrowth factor receptor during the entry process in HFFs. The instantinventors found that pre-treatment of viral particles with soluble formsof this cellular molecule might block the respective interaction sitesof the surface of HCMV virions and hence inhibit infection. To testthis, the inventors pre-incubated cell free preparations of HCMV strainTB40/E with variable concentrations of soluble PDGFR-alpha-Fc chimerasfor 2 h before adding them to HFFs and HECs. After 2 h the virus wasremoved and replaced with the appropriate cell culture medium for anovernight incubation. Cultures were then fixed, and the fraction ofinfected cells was determined by indirect immunofluorescence staining ofviral IE antigens. Actually, PDGFR-alpha-Fc inhibited infection of HFFsin a dose dependent manner with an EC₅₀ of about 10-20 ng/ml and acomplete abrogation of infection at 200 ng/ml (FIG. 2A). Unexpectedly,infection of HECs was also inhibited albeit slightly higherconcentrations were needed (EC₅₀=20-50 ng/ml) and reduction wasincomplete (FIG. 2B).

To address the possibility that the effect is rather due to the Fc partof the chimeric molecule than to the growth receptor part, the inventorscompared PDGFR-alpha-Fc with EGFR-Fc and PDGFR-ß-Fc regarding theirinhibitory potential on HCMV infection. Cell free preparations of TB40/Ewere pre-incubated with increasing concentrations of the various Fcchimeras for 2 h. HFFs were then incubated with the mixtures for 2 hfollowed by a medium exchange and an overnight incubation. Evaluation ofthe infection rates by immunofluorescence staining of viral IE antigenshowed that only PDGFR-alpha-Fc blocked infection in a dose dependentfashion, whereas neither PDGFR-beta-Fc nor EGFR-Fc had an effect (FIG.3A). As the Fc-part is identical with all three molecules, theinhibitory effect is obviously due to the growth factor receptor part ofthe PDGFR-alpha-Fc chimera.

Next, it was tested whether soluble PDGFR-alpha-Fc would inhibit notonly strain TB40/E but also other strains of HCMV. The inventorsprepared cell free stocks of five HCMV strains (AD169, Towne, Merlin,VR1814, VHL/E) that represent the envelope glycoprotein variantsdescribed for HCMV (32), pre-incubated them with PDGFR-alpha-Fc at aconcentration (250 ng/ml) that was sufficient for complete inhibition ofstrain TB40/E in the previous dose response experiment. In addition.TB40/F was included, a variant of TB40/E that lacks the pentameric gH/gLcomplex. After pre-incubation of the various HCMV preparations withPDGFR-alpha-Fc for 2 h, the mixture was added to HFFs in a 96-wellformat for 2 h and then replaced with medium. After an overnightincubation, the fraction of infected cells was determined byimmunofluorescence staining of viral immediate early antigen. Allstrains were strongly inhibited by pretreatment with the solublereceptor, and with the exception of strain VR1814 (residual infectionrate <2%) the reduction was complete (FIG. 3B). Remarkably,susceptibility to inhibition by the PDGFR-alpha-Fc was independent ofwhether the strain contains the pentameric glycoprotein complex or not.

Finally, to test whether this inhibitory effect was specific for HCMVthe inventors repeated the experiment and included another herpes virus,HSV-1 strain F. While the inhibitory effect on HCMV was alwaysreproduced, HSV infection was not affected by PFGFR-alpha (data notshown), indicating that the effect is specific for HCMV.

Example 11

Inhibition of HCMV Infection by PDGFR-Alpha Occurs at the Level of ViralEntry

The findings that removal of PDGFRα from the cell surface as well aspre-treatment of virus with soluble PDGFRα abrogated infection suggestinterference with viral entry as the mode of action. It seemed thereforemost likely that PDGFR-alpha-Fc binds directly to HCMV virus particles.The inventors tested this by staining of adsorbed virus particles withthe Fc-fusion proteins. HCMV particles were pre-incubated withPDGFR-alpha-Fc, PDGFR-beta-Fc or EGFR-Fc for 90 min at 37° C. before thevirus was attached to the cells for 90 min on ice. Virus particles werestained for the capsid protein pp150 and bound Fc-fusion proteins. Theanti-human antibody visualized only those particles that werepre-treated with PDGFR-alpha-Fc, indicating that only this growth factorreceptor-chimera binds to the virus (FIG. 4).

The inventors analyzed the mode of inhibition by PDGFR-alpha-Fc. Forthis, the binding of different concentrations of the fusion protein wasquantified by assessing the particle intensities after staining withanti-human antibody (FIG. 5). The resulting EC₅₀ of binding to HCMVparticles was 108 ng/ml, 10 fold higher than the EC₅₀ for inhibition ofHCMV, indicating that PDGFR-alpha-Fc does not only sterically hinderentry of HCMV particles, but also inactivates them. (FIGS. 4 and 5).

To further investigate, which of the initial steps of infection areblocked, the inventors performed a series of experiments that alloweddiscriminating between adsorption and penetration. They used the dualfluorescent virus TB40-BAC_(KL7)-UL32EGFP-UL100mCherry (Sampaio 2013) asit allows to discriminate between enveloped (EGFP-positive and mCherrypositive) and non-enveloped particles (only EGFP positive). Theycompared adsorption and penetration of untreated particles withparticles pre-incubated with 100 ng/ml PDGFR-alpha or beta by countingthe number of enveloped versus naked particles. On both cell types HFFsand HECs, adsorption of PDGFR-alpha-treated particles was reduced (50%on HFFs and 75% on HECs), whereas penetration was affected only infibroblasts (FIG. 6). PDGFR-alpha-treated particles penetrated HFFs 75%less efficient, indicating that soluble PDGFR-alpha-Fc generally hindersHCMV attachment and specifically inhibits penetration of fibroblasts.Several experiments in which the inventors tested different time pointsand concentrations gave similar results.

As the inhibition of penetration indicated that virions treated withPDGFR-alpha-Fc are defective for fusion of their envelope with thecellular plasma membrane, the inventors tested whether the chemicalfusogen PEG was able to rescue this post-attachment inhibition byPDGFR-alpha-Fc. HCMV virus particles were adsorbed to HFFs for 1 h onice. The virus containing medium was then exchanged by medium containingPDGFR-alpha-Fc at a concentration of 200 ng/ml. Inhibition ofpre-adsorbed virus was allowed for 2 more hours on ice, before the cellswere either directly shifted to 37° C. to allow entry or first treatedwith pre-warmed PEG for 30 sec. The PEG was washed off before theaddition of PDGFR-alpha-Fc containing medium. After 2 h of incubation at37° C. the cells were supplied with fresh medium without inhibitor andfurther incubated overnight. After 24 h the cells were fixed and stainedfor the viral immediate early antigens.

PDGFR-alpha-Fc reduced infectivity of already adsorbed viruses to 50%(FIG. 7). This inhibition was completely rescued by addition of PEG,whereas PEG did not increase the infection of untreated control virus,indicating that PDGFR-alpha-Fc inhibits the fusion step of HCMV entry.

As a possible way of inactivation of HCMV, the inventors found thatPDGFR-alpha-Fc binds the viral envelope glycoprotein pUL74. It wasrecently demonstrated that HCMV lacking pUL74 is deficient for fusioninto host cells (42). To test whether pUL74 is an interaction partner ofPDGFR-alpha-Fc, the inventors tested whether gO deficient particles canbe stained with the soluble molecule similarly to wild type particles(shown in FIG. 8). HCMV wild type or UL74stop particles were incubatedwith 500 ng/ml PDGFR-alpha-Fc or PDGFRβ-Fc for 2 h before attachment tothe cells ice. The particles on the cells were visualized with anantibody recognizing the structural protein pp150 and anti-human (FIG.8A). Only virus particles containing the glycoprotein pUL74 were stainedwith the anti-human Fc antibody, indicating that the trimericgH/gL/pUL74 complex is involved in binding of PDGFR-alpha-Fc to virions.

To further investigate this, inhibition assays were performed with theUL74stop virus (FIG. 8 B). As deletion of pUL74 from the virus has asevere effect on infectivity, virions had to be 50 fold concentrated forthe experiment, whereas wild type virus had to be diluted to achievesimilar infection rates. The infectivity of the UL74stop virus did notsignificantly change with increasing doses of PDGFR-alpha-Fc, indicatingthat PDGFR-alpha-Fc might inhibit HCMV infection via blocking gH/gL/gO.

Example 12

Peptides Derived from the Extracellular Domain of PDGFR-Alpha InhibitHCMV Infection

The surprising finding that only PDGFR-alpha-Fc but not EGFR-Fc orPDGFR-beta-Fc inhibits HCMV infection had indicated that the inhibitoryeffect is due to the PDGFR-alpha part of the chimeric molecule, which isactually only the extracellular domain of the native PDGFR-alphatransmembrane molecule. The inventors unexpectedly found that shortpeptides derived from this protein could also inhibit infection, andtherefore tested a set of overlapping 40mer peptides covering the wholesequence of the extracellular PDGFR-alpha domain regarding theinhibitory potential of the individual peptides. Cell free preparationsof strain TB40/E were pre-incubated with the individual peptides atconcentrations reaching from 0.05-50 nmol/ml for 2 h and the mixtureswere then incubated with HFF cultures in a 96-well format. The variouspeptides differed greatly regarding their inhibitory potential with aregion between aa120 and aa280 being absolutely ineffective and thepeptides surrounding this region having the highest anti-HCMV effect(FIG. 9). The peptide between aa90 and aa130 was particularly effectivewith an EC₅₀ of 2 nmol/ml an almost complete inhibition at 10 nmol/mlmaximal inhibition.

Example 13

Quantification of the Inhibitory Potential of PDGFR-Alpha-Fc Variantswith Small Deletions within the Proposed Ligand Binding Sites on HCMVInfection

Deletion mutant PDGFR-alpha-Fc proteins set forth below and non-deletedPDGFR-alpha-Fc were expressed in 293T cells and purified using proteinA. These proteins were initially diluted in cell culture medium to aconcentration of 8000 ng/ml and were subsequently further diluted in arow of 2-fold dilutions to a minimum concentration of 4 ng/ml. In theinhibition assays, controls were used that contain the same amount ofdilution medium and protein dilution buffer in order to rule out theoccurrence of a non-specific inhibition of binding through therespective buffers. Diluted probes containing deletion mutants ofPDGFR-alpha-Fc or whole PDGFR-alpha-Fc (without deletions) were mixed ata ratio of 1:1 with HCMV expressing luciferase and subsequentlyincubated for 2 h at 37° C. These mixtures were subsequently used ininfection assays of human fibroblasts. After 2 h incubation of cellswith the virus and respectively diluted deletion mutants or non-deletedPDGFR-alpha-Fc as control were removed from the cells and the cells wereincubated for additional 24 h in cell culture medium. Thereafter, theactivity of the luciferase was determined as a measure of the extent ofinfection. The background noise measured in the controls with probescontaining no deletion mutants of PDGFR-alpha-Fc or without wholePDGFR-alpha-Fc were subtracted from the measurements with deletionmutants of PDGFR-alpha-Fc and whole PDGFR-alpha-Fc, respectively.

Experimental Design:

Cells: HFF at 1.5×10⁴/well seeded the day before on 96-well flat bottomcell culture plates coated freshly with 0.1% gelatin

Virus: BAC4 GLuc (yields 60-70% infection at 1:50 dilution; expressesGaussia luciferase under control of the HCMV LE promotor)

Soluble Receptor:

Recombinant Human PDGFR alpha Fc Chimera and variants with smalldeletions within the predicted ligand binding sites. All Proteins wereexpressed in HEK 293T cells and purified using Protein A sepharose. Theproteins were eluted in elution buffer (Thermo) with 10% 1 M Tris pH 8.

Treatment

Pre-Incubation of Virus with the Recombinant Proteins

For each recombinant Protein a 2-fold dilution series starting with 8μg/ml was prepared. As a negative reference sample control dilutionseries containing the same volumes of Elution buffer were prepared.PDGFR-alpha-Fc serves as a positive control.

Total volume per dilution: 120 N1

Protein cone. Vol protein + BCA (E2) % dilution buffer Volume [μg/ml]for 8 μg/ml for 8 μg MEM5G delM1334139 21.5 37.2 89.3 151 del V184-G18611.2 71.4 171.4 69 del N204-208 80.9 9.9 21.7 216 del242-247 20.6 38.893.2 147 del261-264 16.2 49.4 118.5 121 del272-275 17.5 45.7 109.7 130del296-300 82.7 9.7 23.2 217 PDGFR-alpha-Fc 12.6 63.5 152.4 88 Conc.8000 4000 2000 1000 500 250 125 62.5 31.25 15.63 7.81 3.9 [ng/ml]

-   -   100 μl of each inhibitor dilution were mixed with 100 N1 of HCMV        BAC4Gluc (1:25 diluted)    -   =>effective concentration of soluble receptor after addition of        virus [ng/ml]:

Conc. 4000 2000 1000 500 250 125 [ng/ml] Conc. 62.5 31.25 15.63 7.81 3.9195 [ng/ml]

-   -   incubate for 2 h at 37° C.

Infection:

-   -   Cell culture medium was replaced with the virus-receptor        mixtures    -   Cultures were incubated for 2 h at 37° C.    -   After 2 h, virus was removed and replaced with medium.    -   Cultures were then incubated o/n.

Measurement of Gaussia luciferase:

-   -   The Luciferase containing culture media was removed from the        cells. A proportion (20 μl) was mixed with Gaussia substrate        Coelenterazine and light emission was measured at 492 nm.    -   The light emission of samples treated with only buffer was        subtracted from the values of the respective samples.    -   Cells were fixed with 80% acetone for 5 min at RT to allow for        IE staining at a later time point.    -   The results of these experiments are shown in FIG. 10.

Example 14

Focus Expansion Assays with the Repaired Strain Merlin (InitialInfection with Supernatant)

The effect of a substance of interest on viral spread is tested by afocus expansion assay essentially as previously described (Sinzger etal., 1997) with the following modifications. Instead of co-culturinginfected with uninfected cells, indicator cells are directly infectedwith cell-free infectious preparations of the repaired strain Merlin(suitable for conditional expression of RL13 and UL128L). HFFs (or otherindicator cells of choice), seeded in gelatin-coated 96-well plates at adensity of 15,000 cells/well are infected with a virus dose resulting inabout 50 infected cells/well, and are subsequently cultured for 7 daysin the presence or absence of the substance to be tested. Plates arethen fixed with 80% acetone for 5 min at ambient temperature and stainedfor HCMV immediate-early antigen by indirect immunofluorescence usingprimary antibody E13 (Argene) and secondary antibody Cy3-goat anti-mouseIgG F(ab′)₂ (Jackson ImmunoResearch). Nuclei of all cells are stainedwith DAPI. The number of infectious foci per well is counted;“infectious foci” being defined as clusters of at least three infectedcells. In addition, the number of infected cells of randomly selectedinfectious foci is counted and “focus size” is given as infectedcells/focus. The distribution of values for “focus size” is plotted foreach combination of substance with one dot representing one focus, andvirus and values of the central tendency (mean or median) are plotted inaddition. The results are shown in FIG. 11.

Focus Expansion Assays with Clinical Isolates or Stain Merlin (InitialInfection by Coculture):

The effect of a substance of interest on viral spread is tested by afocus expansion assay essentially as previously described (Sinzger etal., 1997). Aliquots of infected cell cultures (HFFs or HFFF-tet cellswith about 10% CPE) are thawed, washed with MEM and co-cultured with an100-fold excess of uninfected indicator cells (e.g. fibroblasts,endothelial cells or epithelial cells) for 7 days in gelatin-coated96-well plates in the presence or absence of the substance to be tested.Plates are then fixed with 80% acetone for 5 min at ambient temperatureand stained for HCMV immediate-early antigen by indirectimmunofluorescence using primary antibody E13 (Argene) and secondaryantibody Cy3-goat anti-mouse IgG F(ab′)2 (Jackson ImmunoResearch).Nuclei of all cells are stained with DAPI. The number of infectious fociper well is counted; “infectious foci” being defined as clusters of atleast three infected cells. In addition, the number of infected cells ofrandomly selected infectious foci is counted and “focus size” is givenas infected cells/focus. The distribution of values for “focus size” isplotted for each combination of substance with one dot representing onefocus, and virus and values of the central tendency (mean or median) areplotted in addition.

REFERENCES

-   1. Adler, B., L. Scrivano, Z. Ruzcics, B. Rupp, C. Sinzger, and U.    Koszinowski. 2006. Role of human cytomegalovirus UL131A in cell    type-specific virus entry and release. The Journal of general    virology 87:2451-2460.-   2. Adler, B., and C. Sinzger. 2013. Cytomegalovirus Inter-Strain    Variance in Cell-Type Tropism. In M. J. Reddehase (ed.),    CYTOMEGALOVIRUSES: From Molecular Pathogenesis to Intervention,    vol. 1. Caister Academic Press, Norfolk.-   3. Ariza-Heredia, E. J., L. Nesher, and R. F. Chemaly. 2014.    Cytomegalovirus diseases after hematopoietic stem cell    transplantation: a mini-review. Cancer Lett 342:1-8.-   4. Burke, H. G., and E. E. Heldwein. 2015. Crystal Structure of the    Human Cytomegalovirus Glycoprotein B. PLoS Pathog 11:e1005227.-   5. Ciferri, C., S. Chandramouli, A. Leitner, D. Donnarumma, M. A.    Cianfrocco, R. Gerrein, K. Friedrich, Y. Aggarwal, G. Palladino, R.    Aebersold, N. Norais, E. C. Settembre, and A. Carfi. 2015. Antigenic    Characterization of the HCMV gH/gJgO and Pentamer Cell Entry    Complexes Reveals Binding Sites for Potently Neutralizing Human    Antibodies. PLoS Pathog 11:e1005230.-   6. Connolly, S. A., J. O. Jackson, T. S. Jardetzky, and R.    Longnecker. 2011. Fusing structure and function: a structural view    of the herpesvirus entry machinery. Nat Rev Microbiol 9:369-381.-   7. Cranage, M. P., T. Kouzarides, A. T. Bankier, S. Satchwell, K.    Weston, P. Tomlinson, B. Barrell, H. Hart, S. E. Bell, A. C. Minson,    and et al. 1986. Identification of the human cytomegalovirus    glycoprotein B gene and induction of neutralizing antibodies via its    expression in recombinant vaccinia virus. EMBO J 5:3057-3063.-   8. Cranage, M. P., G. L. Smith, S. E. Bell, H. Hart, C. Brown, A. T.    Bankier, P. Tomlinson, B. G. Barrell, and T. C. Minson. 1988.    Identification and expression of a human cytomegalovirus    glycoprotein with homology to the Epstein-Barr virus BXLF2 product,    varicella-zoster virus gpll, and herpes simplex virus type I    glycoprotein H. Journal of virology 62:1416-1422.-   9. Eisenberg, R. J., D. Atanasiu, T. M. Cairns, J. R. Gallagher, C.    Krummenacher, and G. H. Cohen. 2012. Herpes virus fusion and entry:    a story with many characters. Viruses 4:800-832.-   10. Falk, J. J., K. L. Sampaio, C. Stegmann, D. Lieber, B.    Kropff, M. Mach, and C. Sinzger. 2016. Generation of a Gaussia    luciferase-expressing endotheliotropic cytomegalovirus for screening    approaches and mutant analyses. Journal of Virological Methods.-   11. Feire, A. L., H. Koss, and T. Compton. 2004. Cellular integrins    function as entry receptors for human cytomegalovirus via a highly    conserved disintegrin-like domain. Proc. Natl. Acad. Sci. USA    101:15470-15475.-   12. Fouts, A. E., P. Chan, J.-P. Stephan, R. Vandlen, and B.    Feierbach. 2012. Antibodies against the gH/gL/UL128/UL130/UL131    Complex Comprise the Majority of the Anti-Cytomegalovirus (Anti-CMV)    Neutralizing Antibody Response in CMV Hyperimmune Globulin. Journal    of virology 86:7444-7447.-   13. Gerna, G., A. Sarasini, M. Patrone, E. Percivalle, L.    Fiorina, G. Campanini, A. Gallina, F. Baldanti, and M. G.    Revello. 2008. Human cytomegalovirus serum neutralizing antibodies    block virus infection of endothelial/epithelial cells, but not    fibroblasts, early during primary infection. Journal of General    Virology 89:853-865.-   14. Goodfellow. I. G., D. J. Evans, A. M. Blom, D. Kerrigan, J. S.    Miners, B. P. Morgan, and O. B. Spiller. 2005. Inhibition of    coxsackie B virus infection by soluble forms of its receptors:    binding affinities, altered particle formation, and competition with    cellular receptors. Journal of virology 79:12016-12024.-   15. Gwee, A., N. Curtis, T. G. Connell, S. Garland, and A. J.    Daley. 2014. Ganciclovir for the treatment of congenital    cytomegalovirus: what are the side effects? Pediatr Infect Dis J    33:115.-   16. Hahn, G., M. G. Revello, M. Patrone, E. Percivalle, G.    Campanini, A. Sarasini, M. Wagner, A. Gallina, G. Milanesi, U.    Koszinowski, F. Baldanti, and G. Gerna. 2004. Human cytomegalovirus    UL131-128 genes are indispensable for virus growth in endothelial    cells and virus transfer to leukocytes. Journal of virology    78:10023-10033.-   17. Haqqani, A. A., and J. C. Tilton. 2013. Entry inhibitors and    their use in the treatment of HIV-1 infection. Antiviral Res    98:158-170.-   18. Heldwein, E. E. 2016. gH/gL supercomplexes at early stages of    herpesvirus entry. Curr Opin Virol 18:1-8.-   19. Hirst, S. J., P. J. Barnes, and C. H. Twort. 1996. PDGF    isoform-induced proliferation and receptor expression in human    cultured airway smooth muscle cells. The American journal of    physiology 270:L415-428.-   20. Huber, M. T., and T. Compton. 1998. The human cytomegalovirus    UL74 gene encodes the third component of the glycoprotein    H-glycoprotein L-containing envelope complex. Journal of virology    72:8191-8197.-   21. Isaacson, M. K., A. L. Feire, and T. Compton. 2007. Epidermal    growth factor receptor is not required for human cytomegalovirus    entry or signaling. J. Virol. 81:6241-6247.-   22. Kaye, J. F., U. A. Gompels, and A. C. Minson. 1992. Glycoprotein    H of human cytomegalovirus (HCMV) forms a stable complex with the    HCMV UL115 gene product. The Journal of general virology 73 (Pt    10):2693-2698.-   23. Kropff, B., M. P. Landini, and M. Mach. 1993. An ELISA using    recombinant proteins for the detection of neutralizing antibodies    against human cytomegalovirus. J Med Virol 39:187-195.-   24. Li, L., J. A. Nelson, and W. J. Britt. 1997. Glycoprotein    H-related complexes of human cytomegalovirus: identification of a    third protein in the gCIII complex. Journal of virology    71:3090-3097.-   25. Lieber, D., D. Hochdorfer, D. Stoehr, A. Schubert, R. Lotfi, T.    May, D. Wirth, and C. Sinzger. 2015. A permanently growing human    endothelial cell line supports productive infection with human    cytomegalovirus under conditional cell growth arrest. Biotechniques    59:127-136.-   26. Macagno, A., N. L. Bernasconi, F. Vanzetta, E. Dander, A.    Sarasini, M. G. Revello, G. Gerna, F. Sallusto, and A.    Lanzavecchia. 2010. Isolation of Human Monoclonal Antibodies That    Potently Neutralize Human Cytomegalovirus Infection by Targeting    Different Epitopes on the gH/gL/UL128-131A Complex. Journal of    virology 84:1005-1013.-   27. Mach, M., B. Kropff, P. Dal Monte, and W. Britt. 2000. Complex    formation by human cytomegalovirus glycoproteins M (gpUL100) and N    (gpUL73). Journal of virology 74:11881-11892.-   28. May, T., M. Butueva, S. Bantner, D. Markusic, J. Seppen, R. A.    MacLeod, H. Weich, H. Hauser, and D. Wirth. 2010. Synthetic gene    regulation circuits for control of cell expansion. Tissue Eng Part A    16:441-452.-   29. Pinkert, S., D. Westermann, X. Wang, K. Klingel, A. Dorner, K.    Savvatis, T. Grossl, S. Krohn, C. Tschope, H. Zeichhardt, K.    Kotsch, K. Weitmann, W. Hoffmann, H. P. Schultheiss, O. B.    Spiller, W. Poller, and H. Fechner. 2009. Prevention of cardiac    dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible    expression of a soluble coxsackievirus-adenovirus receptor.    Circulation 120:2358-2366.-   30. Planitzer, C. B., M. D. Saemann, H. Gajek, M. R. Farcet,    and T. R. Kreil. 2011. Cytomegalovirus neutralization by hyperimmune    and standard intravenous immunoglobulin preparations.    Transplantation 92:267-270.-   31. Rasmussen, L. E., R. M. Nelson, D. C. Kelsall, and T. C.    Merigan. 1984. Murine monoclonal antibody to a single protein    neutralizes the infectivity of human cytomegalovirus. Proc. Natl.    Acad. Sci. USA 81:876-880.-   32. Sinzger, C., G. Hahn, M. Digel, R. Katona, K. L. Sampaio, M.    Messerle, H. Hengel, U. Koszinowski, W. Brune, and B. Adler. 2008.    Cloning and sequencing of a highly productive, endotheliotropic    virus strain derived from human cytomegalovirus TB40/E. The Journal    of general virology 89:359-368.-   33. Somceanu, L., A. Akhavan, and C. S. Cobbs. 2008.    Platelet-derived growth factor-alpha receptor activation is required    for human cytomegalovirus infection. Nature 455:391-395.-   34. Urban, S., R. Bartenschlager, R. Kubitz, and F. Zoulim. 2014.    Strategies to inhibit entry of HBV and HDV into hepatocytes.    Gastroenterology 147:48-64.-   35. Vanarsdall. A. L., T. W. Wisner, H. Lei, A. Kazlauskas,    and D. C. Johnson. 2012. PDGF receptor-alpha does not promote HCMV    entry into epithelial and endothelial cells but increased quantities    stimulate entry by an abnormal pathway. PLoS Pathog 8:e1002905.-   36. Wang, D., F. Li, D. C. Freed, A. C. Finnefrock, A. Tang, S. N.    Grimes, D. R. Casimiro, and T.-M. Fu. 2011. Quantitative analysis of    neutralizing antibody response to human cytomegalovirus in natural    infection. Vaccine 29:9075-9080.-   37. Wang, D., and T. Shenk. 2005. Human cytomegalovirus UL131 open    reading frame is required for epithelial cell tropism. Journal of    virology 79:10330-10338.-   38. Wang, X., D. Y. Huang, S.-M. Huong, and E.-S. Huang. 2005.    Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. Nat.    Med. 11:515-521.-   39. Wang, X., S.-M. Huong, M. L. Chiu, N. Raab-Traub, and E.-S.    Huang. 2003. Epidermal growth factor receptor is a cellular receptor    for human cytomegalovirus. Nature 424:456-461.-   40. Wassaf, D., G. Kuang, K. Kopacz, Q. L. Wu, Q. Nguyen, M.    Toews, J. Cosic, J. Jacques, S. Wiltshire, J. Lambert, C. C.    Pazmany, S. Hogan, R. C. Ladner, A. E. Nixon, and D. J.    Sexton. 2006. High-throughput affinity ranking of antibodies using    surface plasmon resonance microarrays. Analytical biochemistry    351:241-253.-   41. Yanagawa, B., O. B. Spiller, D. G. Proctor, J. Choy, H.    Luo, H. M. Zhang. A. Suarez, D. Yang, and B. M. McManus. 2004.    Soluble recombinant coxsackievirus and adenovirus receptor abrogates    coxsackievirus b3-mediated pancreatitis and myocarditis in mice. The    Journal of infectious diseases 189:1431-1439.-   42. Zhou, M., J. M. Lanchy, and B. J. Ryckman. 2015. Human    Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All    Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a    Distinct Mechanism. Journal of virology 89:8999-9009.

FIGURE DESCRIPTION

FIG. 1: Effect of siRNA-mediated knockdown of growth factor receptors oninfection efficiency in fibroblasts (A) and endothelial cells (B).

FIG. 2: Inhibitory effect of soluble PDGFR-alpha-Fc chimeras on HCMVinfection of fibroblasts (A) and endothelial cells (B). Viruspreparations of strain TB40/E were pretreated for 2 h with PDGFR-alphaat indicated concentrations and then added to cell cultures overnight.Cells were fixed and stained for viral IE antigens. Infections rateswere calculated as the ratio of IE antigen-positive cells/total cellnumber.

FIG. 3: The inhibitory effect of soluble PDGFR-alpha is specific andaffects various HCMV strains. A: The soluble growth receptor moleculesPDGFR-alpha-Fc, PDGFR-beta-Fc and EGFR-Fc were compared regarding theirinhibitory potential on infection of HFFs by HCMV strain TB40/E. Viruspreparations were pretreated for 2 h with the respective growth receptorat indicated concentrations and then added to cell cultures overnight.Cells were fixed and stained for viral IE antigens. Infections rateswere calculated as the ratio of IE antigen-positive cells/total cellnumber. B: The potential of PDGFR-alpha-Fc to inhibit fibroblastinfection with HCMV strains other than TB40/E was tested using acollection of strains that represent all known glycoprotein variants.Infectious supernatants of the different strains were diluted to ˜MOI Iin MEM. The virus preparations were either pre-incubated with MEM (nodrug) or MEM containing 0.25 μg/ml PDGFR-alpha-Fc.

FIG. 4: Binding of soluble PDGFR-Fc chimeras to HCMV particles. Viruspreparations of strain TB40/E were pretreated for 2 h withPDGFR-alpha-Fc, PDGFR-beta-Fc or EGFR-Fc and then incubated with thecells for 90 min on ice. Cells were fixed and stained for the viralstructural protein pUL32 (red) and for Fc (green).

FIG. 5: Quantification of PDGFR-alpha-Fc binding to HCMV particles.Virus preparations of strain TB40/E were pre-incubated with variousconcentrations of PDGFR-alpha-Fc. Binding of the Fc-protein was assessedafter the cells were incubated for 90 min with the virus/PDGFR-alpha-Fcmixture by staining for the viral structural protein pUL32 (red) and forFc (green) followed by quantification of signal intensities. In aparallel experiment HFFs were incubated with the same mixture for 24hours and stained for the viral immediate early antigens to determinethe infection rates resulting from pretreatment with the differentPDGFR-alpha-Fc concentrations.

FIG. 6: Effect of soluble PDGFR-alpha on adsorption and penetration ofHCMV. Adsorption (A) and penetration (B) of virus particles to HFFs andHECs was analyzed by visualization of dual fluorescent HCMV particlesafter 2 h of pre-incubation with 100 ng/ml soluble Fc-chimeras.Adsorption was assessed by counting the total number of bound virusparticles (pUL32 EGFP signals) after 2 h incubation with the cells (A).Penetration was assessed by counting the fraction of total virusparticles that is lacking the envelope (pUL100 mCherry signal) (B). Onerepresentative experiment out of three is shown. C: Examples ofmicroscopic images taken in HFFs.

FIG. 7: Post adsorption inhibitory effect of soluble PDGFR-alpha. Viruspreparations were adsorbed to fibroblasts on ice, before 200 ng/mlPDGFR-alpha-Fc was added. After 2 h the cells were then either directlyshifted to 37° C. or treated with the chemical fusogen PEG. Theresulting infection rates were assessed by staining for the viralimmediate early antigens. The mean values of 3 independent experimentsare shown in A, error bars indicate SEM. Representativeimmunofluorescence images are shown in B.

FIG. 8: pUL74 is the viral interaction partner of PDGFR-alpha-Fc. Viruspreparations of strain TB40-BAC4 or TB40-BAC4UL74stop were pretreatedfor 2 h with PDGFR-alpha-Fc. A: HFFs were fixed after 90 min ofincubation with the virus-inhibitor mixture followed by staining for theviral structural protein pUL32 (red) and for Fc (green). B: Wild type orpUL74stop virus preparations were pre-incubated for 2 h withPDGFR-alpha-Fc before infection of HFFs or HECs was allowed. Wild typeor UL74stop virus preparations were diluted or concentrated respectivelyto obtain similar infection rates. Infection rates were determined bycalculation of the number of immediate early positive nuclei over totalDAPI stained nuclei per image. Out of three independent experiments oneis shown.

FIG. 9: Inhibitory effect of PDGFR-alpha-derived peptides: A:Neutralizing effect of 40mer peptides (3.125 nmol/ml) derived from theextracellular domain of PDGFR-alpha on infection of endothelial cellsand fibroblasts. B, C: Dose response curves of peptide GT40 (position 4in Panel A) in fibroblasts (B) and endothelial cells (C).

FIG. 10: Inhibitory potential of different PDGFR-alpha-Fc derivativesagainst HCMV infection of fibroblasts. The deletions target sites thatwere predicted to be involved in binding of PDGFR-alpha to PDGF-A orPDGF-B. PDGFR-alpha-Fc fusion proteins deleted at the indicatedpositions were diluted to different concentrations and preincubated withHCMV strain TB40-BAC4-IE-Gluc for 2 h before infection of HFFs. On thefollowing day, infection was measured by addition of the luciferasesubstrate coelenterazine and detection of the resulting luminescence.The degree of inhibition is determined as the ratio of values obtainedwith the respective protein concentration to the values measured insamples without PDGFR-alpha-Fc derivatives. PDGFR-alpha-Fc serves as apositive control.

FIG. 11: Effect of peptides on cell-to-cell-spread of strain Merlin.Fibroblasts infected laboratory strain Merlin (with repaired RL13 andUL128L gene regions) were incubated for 7 days with the peptides asindicated at a concentration of 60 nmol/ml. Control cultures wereuntreated or incubated in the presence of hyperimmunoglobulin (cytotect1/100, 0.5 mg plasma protein/ml). Monolayers were fixed, and infectedcells were visualized by indirect immunofluorescence staining of HCMVimmediate early antigens. (A) The number of infectious foci per well wascounted, and the reduction of the focus number by the respective peptideis shown as compared to untreated control. Bars represent mean values of2 independent experiments, error bars represent the standard error ofthe mean. (B) For selected peptides, the numbers of infected cells perfocus were counted. The data from one out of two experiments (yieldingsimilar results) is shown. One dot represents the number of infectedcells of an individual focus. Bars indicate mean values of all foci.GD30 (SEQ ID No. 11) is a shortened version of GT40 (SEQ ID No. 12).NV40 corresponds to SEQ ID No. 13. LT53_cyc is a cyclic version of GT40.

FIG. 12: Effect of peptides on cell-to-cell-spread of an HCMV clinicalisolate. Fibroblasts infected by (A) clinical isolates and (B)laboratory strain Merlin (with repaired RL13 and UL128L gene regions)were co-cultured with a 100-fold excess of uninfected indicatorfibroblasts for 7 days in the presence of peptides as indicated at aconcentration of 60 nmol/ml. Control cultures were untreated orincubated in the presence of hyperimmunoglobulin (cytotect 1/100, 0.5 mgplasma protein/ml). Monolayers were fixed, and infected cells werevisualitzed by indirect immunofluorescence staining of HCMV immediateearly antigens. The numbers of infected cells per focus were counted.One dot represents the number of infected cells of an individual focus.Bars indicate mean values of all foci. GD30 (SEQ ID No. 11) is ashortened version of GT40 (SEQ ID No. 12). LT53_cyc is a cyclic versionof GT40. NV40 corresponds to SEQ ID No. 13.

1. A method for treatment of a subject that has been infected by HCMV,comprising: administering to said subject a soluble PDGFR-alpha-Fcchimera, wherein said soluble PDGFR-alpha-Fc chimera comprises aPDGFR-alpha sequence selected from the following group: I. SEQ ID No. 2consisting of amino acides 24 to amino acids 524 of SEQ ID No. 1:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRS E,

II. a sequence having 90% or more identity to SEQ ID No. 2, III. asequence that is a truncated sequence of SEQ ID No. 2 with at least 45amino acids or a sequence having 90% or more identity to said truncatedSEQ ID No. 2, and IV. variants of sequences according to items I., II.,III. having substitutions atone or more of the following positions(numbering adhered to SEQ ID. No. 1): Ile-30, Glu-52, Ser-66, Ser-67,Asp-68, Leu-80, Ser-89, His-162, Pro-169, Asp-173, Ile-188, Val-193,Lys-194, Glu-213, Lys-304, Thr-320, His-334, Arg-340, Ile-373, Lys-378,Ala-396, Ala-401, Thr-436, Thr-440, Ile-453, Val-469, Ile-476, Ser-478,Asp-480, Ser-482, Arg-487.
 2. The method according to claim 1, whereinsaid soluble PDGFR-alpha-Fc chimera has at least one of the followingmutations or deletions within SEQ ID No. 2 (numbering adhered to SEQ ID.No. 1): i. Deletion of aa 150-189, ii. SEQ ID No. 2 having at least onepoint mutation in the protein region as specified in the above item i.3. The method according to claim 1, wherein said soluble PDGFR-alpha-Fcchimera has at least one of the following mutations or deletions withinSEQ ID No. 2 (numbering is adhered to SEQ ID No. 1): i) Deletion ofamino acids M133-I139; ii) Deletion of amino acids V184-G185; iii)Deletion of amino acids N204-Y206; iv) Deletion of amino acidsT259-E262; v) Deletion of amino acids Q294-E298; vi) SEQ ID No. 2 havingat least one point mutation in at least one of the protein regions asspecified above under items i., ii., iii., iv., or v.
 4. The methodaccording to claim 1, wherein said subject is: (a) a pregnant woman whois infected by HCMV, (b) a congenitally HCMV-infected child, (c) a bonemarrow transplant recipient infected with HCMV, or (d) a solid organtransplant recipients infected with HCMV.
 5. The method according toclaim 1, wherein said soluble PDGFR-alpha-Fc chimera comprises asequence of SEQ ID No.
 3. 6. The method according to claim 1, whereinsaid soluble PDGFR-alpha-Fc chimera comprises a sequence of human Fc asdepicted in SEQ ID No.
 8. 7. The method according to claim 1, whereinsaid soluble PDGFR-alpha-Fc chimera is suitable for binding specificallyto HCMV.
 8. A method for treatment of a subject that has been infectedby HCMV comprising: administering to said subject a PDGFR-alpha peptidefragment, wherein said peptide fragment is selected from: I. SEQ ID No.9; II. SEQ ID No. 10; M. SEQ ID No. 11; IV. SEQ ID No. 12; V. SEQ ID No.13; VI. a peptide fragment of SEQ ID No. 9, SEQ ID No. 10, SEQ ID No.11, SEQ ID No. 12, or SEQ ID No. 13, any of them having at least 10amino acids, and VII. a variant of the above items I to VI that exhibitsat least 80% sequence identity to the peptide having the sequence of SEQID No. 9 or SEQ ID No. 10 or SEQ ID No. 11 or SEQ ID No. 12 or SEQ IDNo. 13 that exhibits at least 80% sequence identity to the peptidefragment of SEQ ID No. 9 or SEQ ID No. 10 or SEQ ID No. 11 or SEQ ID No.12 or SEQ ID No. 13, said variant having a length of at least 10 aminoacids.
 9. The method according to claim 8, wherein said subject is: (a)a pregnant woman that is infected by HCMV, (b) a congenitallyHCMV-infected child, (c) a bone marrow transplant recipient infectedwith HCMV or at risk of HCMV infection, or (d) a solid organ transplantrecipient infected with HCMV or at risk with HCMV infection. 10.(canceled)
 11. (canceled)
 12. (canceled)
 13. (canceled)
 14. (canceled)15. A method for prophylaxis of HCMV infection in a subject that has notyet been infected by HCMV, comprising: administering to said subject asoluble PDGFR-alpha-Fc chimera, wherein said soluble PDGFR-alpha-Fcchimera comprises a PDGFR-alpha sequence selected from the followinggroup: I. SEQ ID No. 2 consisting of amino acids 24 to amino acids 524of SEQ ID No. 1: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRE LKLVAPTLRSE,

II. a sequence having 90% or more identity to SEQ ID No. 2, III. asequence that is a truncated sequence of SEQ ID No. 2 with at least 45amino acids or a sequence having 90% or more identity to said truncatedSEQ ID No. 2, and IV. variants of sequences according to items I., II.,III. having substitutions atone or more of the following positions(numbering adhered to SEQ ID. No. 1): Ile-30, Glu-52, Ser-66, Ser-67,Asp-68, Leu-80, Ser-89, His-162, Pro-169, Asp-173, Ile-188, Val-193,Lys-194, Glu-213, Lys-304, Thr-320, His-334, Arg-340, Ile-373, Lys-378,Ala-396, Ala-401, Thr-436, Thr-440, Ile-453, Val-469, Ile-476, Ser-478,Asp-480, Ser-482, Arg-487.
 16. The method according to claim 1, whereinsaid soluble PDGFR-alpha-Fc chimera, has an EC50 value lower than 100ng/ml.
 17. The method according to claim 1, wherein said solublePDGFR-alpha-Fc chimera comprises a PDGFR-alpha sequence having at leastone of the following mutations or deletions within SEQ ID No. 2(numbering is adhered to SEQ ID No. 1): i. Deletion of amino acidsM133-I139 optionally having additional deletions at the N- and/orC-termini of at least one or at least two or at least three N-terminalamino acids and/or at least one or at least two or at least three or atleast four or at least five C-terminal amino acids; further it ispossible also to delete one or two or three or four or five amino acidsless than amino acids M133-I139 at the N-terminus and/or the C-terminus,wherein all possible combinations of fewer deleted amino acids arepossible, provided that at least one amino acid remains deleted in thestretch of amino acids M133-I139, ii. Deletion of amino acids V184-G185optionally having additional deletions at the N- and/or C-termini of atleast one or at least two or at least three N-terminal amino acidsand/or at least one or at least two or at least three or at least fouror at least five C-terminal amino acids, wherein each of the respectivecombinations of additional deletions; Furthermore, it is possible alsoto delete one amino acid less than amino acids V184-G185 at theN-terminus and/or the C-terminus, wherein all possible combinations offewer deleted amino acids are possible, provided that at least one aminoacid remains deleted in the stretch of amino acids V184-G185, iii.Deletion of amino acids N204-Y206 optionally having additional deletionsat the N- and/or C-termini of at least one or at least two or at leastthree N-terminal amino acids and/or at least one or at least two or atleast three or at least four or at least five C-terminal amino acids;furthermore, it is possible also to delete one or two amino acid lessthan amino acids N204-Y206 at the N-terminus and/or the C-terminus,wherein all possible combinations of fewer deleted amino acids arepossible, provided that at least one amino acid remains deleted in thestretch of amino acids N204-Y206; iv. Deletion of amino acids N240-L245(optionally having additional deletions at the N- and/or C-termini of atleast one or at least two or at least three N-terminal amino acidsand/or at least one or at least two or at least three or at least fouror at least five C-terminal amino acids; further it is possible also todelete one or two or three or four or five amino acids less than aminoacids N240-L245 at the N-terminus and/or the C-terminus, wherein allpossible combinations of fewer deleted amino acids are possible,provided that at least one amino acid remains deleted in the stretch ofamino acids N240-L245, v. Deletion of amino acids T259-E262 optionallyhaving additional deletions at the N- and/or C-termini of at least oneor at least two or at least three N-terminal amino acids and/or at leastone or at least two or at least three or at least four or at least fiveC-terminal amino acids, wherein each of the respective combinations ofadditional deletions; further it is possible also to delete one or twoor three or four amino acids less than amino acids T259-E262 at theN-terminus and/or the C-terminus, wherein all possible combinations offewer deleted amino acids are possible, provided that at least one aminoacid remains deleted in the stretch of amino acids T259-E262; vi.Deletion of amino acids K270-T273 optionally having additional deletionsat the N- and/or C-termini of at least one or at least two or at leastthree N-terminal amino acids and/or at least one or at least two or atleast three or at least four or at least five C-terminal amino acids,wherein each of the respective combinations of additional deletions;further it is possible also to delete one or two or three amino acidsless than amino acids K270-T273 at the N-terminus and/or the C-terminus,wherein all possible combinations of fewer deleted amino acids arepossible, provided that at least one amino acid remains deleted in thestretch of amino acids K270-T273; vii. Deletion of amino acids Q294-E298optionally having additional deletions at the N- and/or C-termini of atleast one or at least two or at least three N-terminal amino acidsand/or at least one or at least two or at least three or at least fouror at least five C-terminal amino acids; further it is possible also todelete one or two or three or four amino acids less than amino acidsQ294-E298 at the N-terminus and/or the C-terminus, wherein all possiblecombinations of fewer deleted amino acids are possible, provided that atleast one amino acid remains deleted in the stretch of amino acidsQ294-E298; and viii. SEQ ID No. 2 having at least one point mutation inat least one of the protein regions as specified above under items i.,ii., iii., iv., v., vi, or vii.
 18. The method according to claim 1,wherein said soluble PDGFR-alpha-Fc chimera comprises a PDGFR-alphasequence selected from the following group: I. a sequence having 90% ormore identity to SEQ ID No. 2, II. a sequence that is a truncatedsequence of SEQ ID No. 2 or a sequence having 90% or more identity tosaid truncated SEQ ID No. 2 said sequence having at least 45 aminoacids, and III. variants of sequences according to the yetaforementioned items I. and II., with substitutions at one or more ofthe following positions (numbering is adhered to SEQ ID. No. 1): Ile-30,Glu-52, Ser-66, Ser-67, Asp-68, Lu-80, Ser-89, His-162, Pro-169,Asp-173, Ile-188, Val-193, Lys-194, Glu-213, Lys-304, Thr-320, His-334,Arg-340, Ile-373, Lys-378, Ala-396, Ala-401, Thr-436, Thr-440, Ile-453,Val-469, Ile-476, Ser-478, Asp-480, Ser-482, Arg-487.
 19. The methodaccording to claim 1, wherein said soluble PDGFR-alpha-Fc chimeracomprises a sequence selected from the following group: SEQ ID No. 3:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAK NLLGAENRELKLVAPTLRSE,SEQ ID No. 4: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE, SEQ ID No. 5:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLL GAENRELKLVAPTLRSE,SEQ ID No. 6: QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIP, SEQ ID No. 7:YYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIP.


20. The method according to claim 1, wherein said soluble PDGFR-alpha-Fcchimera further comprises the sequence of human Fc that is SEQ ID No. 8:LTVAGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.


21. A method for inhibiting HCMV entry into a cell, comprising: bringingsaid cell into contact with a soluble PDGFR-alpha-Fc chimera, whereinsaid soluble PDGFR-alpha-Fc chimera comprises a PDGFR-alpha sequenceselected from the following group: I. SEQ ID No. 2 consisting of aminoacids 24 to amino acids 524 of SEQ ID No. 1:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE,

II. a sequence having 90% or more identity to SEQ ID No. 2, III. asequence that is a truncated sequence of SEQ ID No. 2 with at least 45amino acids or a sequence having 90% or more identity to said truncatedSEQ ID No. 2, and IV. variants of sequences according to items I., II.,III. having substitutions atone or more of the following positions(numbering adhered to SEQ ID. No. 1): Ile-30, Glu-52, Ser-66, Ser-67,Asp-68, Leu-80, Ser-89, His-162, Pro-169, Asp-173, Ile-188, Val-193,Lys-194, Glu-213, Lys-304, Thr-320, His-334, Arg-340, Ile-373, Lys-378,Ala-396, Ala-401, Thr-436, Thr-440, Ile-453, Val-469, Ile-476, Ser-478,Asp-480, Ser-482, Arg-487.
 22. A method for inhibiting HCMV entry into acell, comprising: bringing said cell into contact with a PDGFR-alphapeptide fragment, wherein said peptide fragment is selected from: I. SEQID No. 9; II. SEQ ID No. 10; III. SEQ ID No. 11; IV. SEQ ID No. 12; V.SEQ ID No. 13, VI. a peptide fragment of SEQ ID No. 9, SEQ ID No. 10,SEQ ID No. 11, SEQ ID No. 12, or SEQ ID No. 13, any of them having atleast 10 amino acids, and VII. a variant of the above items I to VI thatexhibits at least 80% sequence identity to the peptide having thesequence of SEQ ID No. 9 or SEQ ID No. 10 or SEQ ID No. 11 or SEQ ID No.12 or SEQ ID No. 13 that exhibits at least 80% sequence identity to thepeptide fragment of SEQ ID No. 9 or SEQ ID No. 10 or SEQ ID No. 11 orSEQ ID No. 12 or SEQ ID No. 13, said variant having a length of at least10 amino acids.
 23. A method for inhibiting HCMV entry into a cell,comprising: bringing said cell into contact with a delivery vector fortransferring a nucleic acid sequence encoding a PDGFR-alpha derivedpeptide or fragment thereof suitable for inhibiting HCMV entry, whereinthe peptide or fragment is releasable from the delivery vector to bindto HCMV and inhibit infection of said cell.
 24. The method according toclaim 23, wherein said nucleic acid sequence comprises a PDGFR-alphasequence selected from the following group: I. SEQ ID No. 2 consistingof amino acids 24 to amino acids 524 of SEQ ID No. 1:QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSE,

II. a sequence having 90% or more identity to SEQ ID No. 2, III. asequence that is a truncated sequence of SEQ ID No. 2 with at least 45amino acids or a sequence having 90% or more identity to said truncatedSEQ ID No. 2, and IV. variants of sequences according to items I., II.,III. having substitutions atone or more of the following positions(numbering adhered to SEQ ID. No. 1): Ile-30, Glu-52, Ser-66, Ser-67,Asp-68, Leu-80, Ser-89, His-162, Pro-169, Asp-173, Ile-188, Val-193,Lys-194, Glu-213, Lys-304, Thr-320, His-334, Arg-340, Ile-373, Lys-378,Ala-396, Ala-401, Thr-436, Thr-440, Ile-453, Val-469, Ile-476, Ser-478,Asp-480, Ser-482, Arg-487.
 25. The method according to claim 23, whereinsaid nucleic acid sequence comprises a PDGFR-alpha sequence selectedfrom the following group: I. SEQ ID No. 9; II. SEQ ID No. 10; III. SEQID No. 11; IV. SEQ ID No. 12; V. SEQ ID No. 13, VI. a peptide fragmentof SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, or SEQ IDNo. 13, any of them having at least 10 amino acids, and VII. a variantof the above items I to VI that exhibits at least 80% sequence identityto the peptide having the sequence of SEQ ID No. 9 or SEQ ID No. 10 orSEQ ID No. 11 or SEQ ID No. 12 or SEQ ID No. 13 that exhibits at least80% sequence identity to the peptide fragment of SEQ ID No. 9 or SEQ IDNo. 10 or SEQ ID No. 11 or SEQ ID No. 12 or SEQ ID No. 13, said varianthaving a length of at least 10 amino acids.